



**Cochrane**  
**Library**

Cochrane Database of Systematic Reviews

## Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency (Review)

Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH

Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH.

Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency.

*Cochrane Database of Systematic Reviews* 2018, Issue 3. Art. No.: CD004655.

DOI: 10.1002/14651858.CD004655.pub3.

[www.cochranelibrary.com](http://www.cochranelibrary.com)

## TABLE OF CONTENTS

HEADER . . . . .	1
ABSTRACT . . . . .	1
PLAIN LANGUAGE SUMMARY . . . . .	2
SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . .	4
BACKGROUND . . . . .	7
OBJECTIVES . . . . .	8
METHODS . . . . .	8
Figure 1. . . . .	11
RESULTS . . . . .	16
Figure 2. . . . .	19
Figure 3. . . . .	20
DISCUSSION . . . . .	22
AUTHORS' CONCLUSIONS . . . . .	23
ACKNOWLEDGEMENTS . . . . .	24
REFERENCES . . . . .	24
CHARACTERISTICS OF STUDIES . . . . .	28
DATA AND ANALYSES . . . . .	40
Analysis 1.1. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 1 Serum vitamin B12 levels. . . . .	40
Analysis 1.2. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 2 Number of participants with normalisation of serum vitamin B12 deficiency. . . . .	41
Analysis 1.3. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 3 Adverse events. . . . .	41
Analysis 1.4. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 4 Haemoglobin. . . . .	42
Analysis 1.5. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 5 Mean corpuscular volume. . . . .	42
Analysis 1.6. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 6 Total homocysteine. . . . .	43
Analysis 1.7. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 7 Serum methylmalonic acid. . . . .	43
ADDITIONAL TABLES . . . . .	43
APPENDICES . . . . .	45
WHAT'S NEW . . . . .	62
CONTRIBUTIONS OF AUTHORS . . . . .	62
DECLARATIONS OF INTEREST . . . . .	63
SOURCES OF SUPPORT . . . . .	63
DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . .	63
NOTES . . . . .	64
INDEX TERMS . . . . .	64

[Intervention Review]

# Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency

Haiyan Wang<sup>1</sup>, Linyi Li<sup>2</sup>, Ling Ling Qin<sup>3</sup>, Yanan Song<sup>3</sup>, Josep Vidal-Alaball<sup>4</sup>, Tong Hua Liu<sup>5</sup>

<sup>1</sup>Institute of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. <sup>2</sup>Key Laboratory of Upper Airway Dysfunction-related Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China. <sup>3</sup>Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. <sup>4</sup>Gerència Territorial Catalunya Central, Catalan Health Institute, St Fruitós de Bages, Spain. <sup>5</sup>Graduate Campus, Beijing University of Chinese Medicine, Beijing, China

Contact address: Tong Hua Liu, Graduate Campus, Beijing University of Chinese Medicine, North Third Ring Road No. 11 School range, ChaoYang District, Beijing, 100029, China. [thliu@vip.163.com](mailto:thliu@vip.163.com).

**Editorial group:** Cochrane Metabolic and Endocrine Disorders Group.

**Publication status and date:** New search for studies and content updated (no change to conclusions), published in Issue 3, 2018.

**Citation:** Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency. *Cochrane Database of Systematic Reviews* 2018, Issue 3. Art. No.: CD004655. DOI: 10.1002/14651858.CD004655.pub3.

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

## ABSTRACT

### Background

Vitamin B<sub>12</sub> deficiency is common, and the incidence increases with age. Most people with vitamin B<sub>12</sub> deficiency are treated in primary care with intramuscular (IM) vitamin B<sub>12</sub>. Doctors may not be prescribing oral vitamin B<sub>12</sub> formulations because they may be unaware of this option or have concerns regarding its effectiveness.

### Objectives

To assess the effects of oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency.

### Search methods

We searched CENTRAL, MEDLINE, Embase, and LILACS, as well as the WHO ICTRP and ClinicalTrials.gov. The latest search date was 17 July 2017. We applied no language restrictions. We also contacted authors of relevant trials to enquire about other published or unpublished studies and ongoing trials.

### Selection criteria

Randomised controlled trials (RCTs) comparing the effect of oral versus IM vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency.

### Data collection and analysis

We used standard methodological procedures expected by Cochrane. Our primary outcomes were serum vitamin B<sub>12</sub> levels, clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, and adverse events. Secondary outcomes were health-related quality of life, acceptability to patients, haemoglobin and mean corpuscular volume, total homocysteine and serum methylmalonic acid levels, and socioeconomic effects. We used GRADE to assess the quality of the evidence for important outcomes. We did not perform meta-analyses due to the small number of included trials and substantial clinical heterogeneity.

## Main results

Three RCTs met our inclusion criteria. The trials randomised 153 participants (74 participants to oral vitamin B<sub>12</sub> and 79 participants to IM vitamin B<sub>12</sub>). Treatment duration and follow-up ranged between three and four months. The mean age of participants ranged from 38.6 to 72 years. The treatment frequency and daily dose of vitamin B<sub>12</sub> in the oral and IM groups varied among trials. Only one trial had low or unclear risk of bias across all domains and outcome measures. Two trials reported data for serum vitamin B<sub>12</sub> levels. The overall quality of evidence for this outcome was low due to serious imprecision (low number of trials and participants). In two trials employing 1000 µg/day oral vitamin B<sub>12</sub>, there was no clinically relevant difference in vitamin B<sub>12</sub> levels when compared with IM vitamin B<sub>12</sub>. One trial used 2000 µg/day vitamin B<sub>12</sub> and demonstrated a mean difference of 680 pg/mL (95% confidence interval 392.7 to 967.3) in favour of oral vitamin B<sub>12</sub>. Two trials reported data on adverse events (very low-quality evidence due to risk of performance bias, detection bias, and serious imprecision). One trial stated that no treatment-related adverse events were seen in both the oral and IM vitamin B<sub>12</sub> groups. One trial reported that 2 of 30 participants (6.7%) in the oral vitamin B<sub>12</sub> group left the trial early due to adverse events. Orally taken vitamin B<sub>12</sub> showed lower treatment-associated costs than IM vitamin B<sub>12</sub> in one trial (low-quality evidence due to serious imprecision). No trial reported on clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, health-related quality of life, or acceptability of the treatment scheme.

## Authors' conclusions

Low quality evidence shows oral and IM vitamin B<sub>12</sub> having similar effects in terms of normalising serum vitamin B<sub>12</sub> levels, but oral treatment costs less. We found very low-quality evidence that oral vitamin B<sub>12</sub> appears as safe as IM vitamin B<sub>12</sub>. Further trials should conduct better randomisation and blinding procedures, recruit more participants, and provide adequate reporting. Future trials should also measure important outcomes such as the clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, health related-quality of life, socioeconomic effects, and report adverse events adequately, preferably in a primary care setting.

## PLAIN LANGUAGE SUMMARY

### Oral vitamin B<sub>12</sub> compared with intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency

#### Review question

Does oral vitamin B<sub>12</sub> have similar effects as intramuscular injections of vitamin B<sub>12</sub> for people with vitamin B<sub>12</sub> deficiency?

#### Background

Vitamin B<sub>12</sub> (cobalamin) is necessary for basic body functions, such as the growth and development of red blood cells and the nervous system. Vitamin B<sub>12</sub> deficiency (a lack of vitamin B<sub>12</sub>) is very common. Many factors contribute to vitamin B<sub>12</sub> deficiency, such as age, blood disease, vegetarian diet, indigestion, use of drugs, as well as poor nutrition. Doctors are more likely to give vitamin B<sub>12</sub> using injections into the muscle (intramuscular injection) because they may be unaware of the option to use oral vitamin B<sub>12</sub> or uncertain about how well it works.

#### Study characteristics

We found three randomised controlled studies (clinical studies where people are randomly put into one of two or more treatment groups). The studies randomised 153 participants (74 participants to oral vitamin B<sub>12</sub> and 79 participants to intramuscular vitamin B<sub>12</sub>). Treatment duration and follow-up ranged between three and four months. The mean age of participants ranged from 39 to 72 years.

#### Key results

Two studies used 1000 µg/day oral vitamin B<sub>12</sub> and showed no relevant difference to intramuscularly applied vitamin B<sub>12</sub> with regard to vitamin B<sub>12</sub> blood levels. One trial used 2000 µg/day vitamin B<sub>12</sub> and showed higher vitamin B<sub>12</sub> blood levels in favour of oral vitamin B<sub>12</sub>. Two studies reported side effects. One study stated that no treatment-related side effects were seen in both the oral and intramuscular vitamin B<sub>12</sub> groups. One study reported that 2 of 30 participants in the oral vitamin B<sub>12</sub> group left the trial early due to side effects. Orally taken vitamin B<sub>12</sub> showed lower treatment-associated costs than intramuscular vitamin B<sub>12</sub> in one trial. No study reported on clinical signs and symptoms of vitamin B<sub>12</sub> deficiency (e.g. fatigue, depression, neurological complications), health-related quality of life, or acceptability of the treatment scheme.

#### Quality of the evidence

The overall quality of the evidence was low or very low, mainly due to the small number of included studies and the low numbers of participants in these studies.

## SUMMARY OF FINDINGS FOR THE MAIN COMPARISON *[Explanation]*

Oral versus intramuscular vitamin B <sub>12</sub> for vitamin B <sub>12</sub> deficiency						
<b>Patient:</b> people with vitamin B <sub>12</sub> deficiency <b>Setting:</b> outpatients <b>Intervention:</b> oral versus IM vitamin B <sub>12</sub>						
Outcomes	IM vitamin B <sub>12</sub>	Oral vitamin B <sub>12</sub>	Relative effect (95% CI)	No. of participants (trials)	Quality of the evidence (GRADE)	Comments
<b>Serum vitamin B<sub>12</sub> levels</b> Normal value: > 300 pg/mL (> 221 pmol/L) Follow-up: 90 days and 4 months	See comment	See comment	Not estimable	153 (3)	⊕⊕○○ low <sup>a</sup>	1 trial (60 participants) used 1000 µg/day oral or IM vitamin B <sub>12</sub> (total dose 15 mg): MD was -11.7 pg/mL (95% CI -29.5 to 6.1) ( <a href="#">Bolaman 2003</a> ). . 1 trial (33 participants) used 2000 µg/day vitamin B <sub>12</sub> (total dose 240 mg) or 1000 µg/day IM vitamin B <sub>12</sub> (total dose 9 mg): MD was 680 pg/mL (95% CI 392.7 to 967.3) in favour of oral vitamin B <sub>12</sub> ( <a href="#">Kuzminski 1998</a> ). 1 trial (60 participants) (using 1000 µg/day oral or IM vitamin B <sub>12</sub> (total dose 90 mg and 15 mg, oral and IM respectively) reported that 27/30 in the IM vitamin B <sub>12</sub> group (90%) and 20/30 in the oral vitamin B <sub>12</sub> group (66.7%) achieved normalisation of serum vitamin B <sub>12</sub> , defined as ≥ 200 pg/mL ( <a href="#">Saraswathy 2012</a> ).

<b>Clinical signs and symptoms</b>	Not reported					
<b>Adverse events</b> Follow-up: 90 days and 3 months	See comment	See comment	Not estimable	120 (2)	⊕○○○ <b>very low<sup>b</sup></b>	<p><a href="#">Bolaman 2003</a> reported no treatment-related adverse events in both the oral and IM vitamin B<sub>12</sub> groups.</p> <p><a href="#">Saraswathy 2012</a> reported that 2/30 participants (6.7%) in the oral vitamin B<sub>12</sub> group left the trial early due to adverse events.</p>
<b>Health-related quality of life</b>	Not reported					
<b>Acceptability</b>	Not reported					
<b>Socioeconomic effects</b> Follow-up: 90 days	See comment	See comment	Not estimable	60 (1)	⊕⊕○○ <b>low<sup>c</sup></b>	<p>Only 1 trial reported data for this outcome (<a href="#">Bolaman 2003</a>). The costs per treatment were USD 80 per person in the oral vitamin B<sub>12</sub> group compared with USD 220 per person in the IM group.</p>

CI: confidence interval; IM: intramuscular; MD: mean difference

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

<sup>a</sup>Downgraded by two levels due to serious imprecision (low numbers of trials and participants); see [Appendix 12](#).

<sup>b</sup>Downgraded by three levels due to risk of bias (performance bias, detection bias) and serious imprecision (low numbers of trials and participants); see [Appendix 12](#).

<sup>c</sup>Downgraded by two levels due to serious imprecision (low numbers of trials and participants); see [Appendix 12](#).



## BACKGROUND

### Description of the condition

Vitamins are a group of substances required for effective human metabolism. Under normal circumstances it is essential that they are present in a person's diet because, with few exceptions, the human body is unable to manufacture them. Vitamins often work together with enzymes, cofactors, and other substances. Vitamin B<sub>12</sub> (cobalamin) is necessary for the development of red blood cells, growth, and nervous system maintenance. The only dietary sources of vitamin B<sub>12</sub> are animal products, such as eggs, fish, and meats. Daily requirements are age-related: the recommended dietary amounts for adults and infants are 1.5 µg and 0.4 µg, respectively (Anonymous 1991; FAO/WHO 1988).

Vitamin B<sub>12</sub> is absorbed in the terminal ileum. This absorption is almost entirely dependent upon the intrinsic factor, a glycoprotein secreted by parietal cells situated in the mucosa of the stomach. Intrinsic factor binds to vitamin B<sub>12</sub>, and the complex is transported across the cell membrane bound to another glycoprotein called transcobalamin. The most common cause of vitamin B<sub>12</sub> deficiency is autoimmune pernicious anaemia, a condition that carries an increased risk of gastric cancer. In pernicious anaemia, absorption is impaired due to intrinsic factor deficiency arising from autoimmune destruction of parietal cells. Other common causes of vitamin B<sub>12</sub> deficiency include gastrectomy, ileal resection, pancreatic insufficiency, and malabsorption syndromes including Crohn's disease and celiac disease. Other less common causes of vitamin B<sub>12</sub> deficiency include use of drugs such as biguanides (metformin), antacids (proton pump inhibitors and H<sub>2</sub> receptors antagonists), aminoglycoside, antibiotics and colchicines, and rarely, malabsorption due to gastrointestinal bacterial overgrowth, congenital defects (e.g. birth transcobalamin deficiency), and infestation. Pure nutritional deficiency is rare and usually occurs only in strict vegans (Watanabe 2013). In some cases, vitamin B<sub>12</sub> deficiency can be a risk factor for cardiovascular disease (Pawlak 2015). It is recommended that vegetarians take vitamin B<sub>12</sub> supplements to prevent vitamin B<sub>12</sub> deficiency (Pawlak 2013).

The prevalence of vitamin B<sub>12</sub> deficiency varies among countries, and manifests in population groups when the vitamin B<sub>12</sub> demand increases whilst the intake remains unchanged or is reduced, such as in infants, pregnant women, and the elderly. The incidence of vitamin B<sub>12</sub> deficiency increases with age, probably due to the fact that elderly people are more likely to suffer from food-cobalamin malabsorption. This malabsorption is caused primarily by gastric atrophy but also by chronic carriage of *Helicobacter pylori*, long-term ingestion of metformin and proton pump inhibitors, and increased chances of having gastric surgery (Andres 2004; De Jager 2010; Lam 2013). The prevalence of vitamin B<sub>12</sub> deficiency in the elderly varies substantially in different studies, with reported figures between 1.5% and 15% (Brito 2015; Clarke

2004; Figlin 2003; MacFarlane 2011; Pennypacker 1992; Rajan 2002; van Walraven 1999). The differences may be due to inconsistent diagnostic criteria for vitamin B<sub>12</sub> deficiency.

As well as varying with age, prevalence also varies with gender and ethnic group: elderly men are more likely to have low vitamin B<sub>12</sub> levels than elderly women. The prevalence of vitamin B<sub>12</sub> deficiency is higher in Europe than in the USA (Lindenbaum 1994; Pennypacker 1992). African and Asian countries have the highest rates of vitamin B<sub>12</sub> deficiency, for example both Kenyan and Indian schoolchildren have a rate above 70%, as well as Indian adults (Allen 2009).

Vitamin B<sub>12</sub> is a cofactor to methylation, which facilitates DNA synthesis and haemopoiesis and maintains neurological function (Green 2013). Vitamin B<sub>12</sub> deficiency can cause serious clinical symptoms such as megaloblastic anaemia, paralysis, dementia, fatigue, and mood disturbance. If left untreated, serious neurological and neuropsychiatric complications can occur. Vitamin B<sub>12</sub> deficiency has also been linked with an increased risk of myocardial infarction and stroke. A recent study reported that there is a relationship between vitamin B<sub>12</sub> deficiency and delirium in elderly patients undergoing cardiac surgery (Schroll 2015).

The diagnosis of vitamin B<sub>12</sub> deficiency is based mainly on blood measurements of serum vitamin B<sub>12</sub> level less than 200 pg/mL (148 pmol/L), complemented with second-line tests including total homocysteine and methylmalonic acid levels, which are metabolic indicators of vitamin B<sub>12</sub> deficiency. Studies have indicated that an estimated 20% of people can present with neuropsychiatric symptoms in the absence of haematological abnormalities (Quadros 2010).

### Description of the intervention

Vitamin B<sub>12</sub> was first isolated in its cyano-form in 1948 (Rickes 1948; Smith 1948), and is now widely used for the treatment of vitamin B<sub>12</sub> deficiency. Most vitamin B<sub>12</sub>-deficient individuals in the UK and other countries are treated with intramuscular vitamin B<sub>12</sub>, and vitamin B<sub>12</sub> replacement has been traditionally administered intramuscularly. Intramuscular vitamin B<sub>12</sub> can be administered in two different forms: cyanocobalamin and hydroxocobalamin. In some countries hydroxocobalamin has completely replaced cyanocobalamin as first choice for vitamin B<sub>12</sub> therapy because it is retained in the body longer and can be administered at intervals of up to three months (BNF 2004).

Several case control and case series studies have since suggested that oral vitamin B<sub>12</sub> has an equal efficacy and safety as intramuscular vitamin B<sub>12</sub> (Andres 2010; Bahadir 2015; Bolaman 2003; Castelli 2011; Kuzminski 1998). However, despite its availability in most countries and its very safe track record, vitamin B<sub>12</sub> is rarely prescribed in the oral form. Two exceptions to this are in Canada and Sweden, where in the year 2000 oral vitamin B<sub>12</sub> accounted for 73% of the total vitamin B<sub>12</sub> prescribed (Nilsson 2005). Possible reasons for doctors not prescribing oral formulations may include

a lack of awareness of this option or concerns regarding unpredictable absorption (Graham 2007; Lederle 1998). In the UK, oral vitamin B<sub>12</sub> is currently not available on National Health Service (NHS) prescription in high-dose formulations.

### Adverse effects of the intervention

Intramuscular vitamin B<sub>12</sub> can cause significant pain, especially in thin people (Elia 1998). While serious adverse reactions are rare, injections can be dangerous in anticoagulated individuals. No adverse effects of oral administration have been reported (Andres 2010).

### How the intervention might work

The mechanism for the intramuscular route is most probably that vitamin B<sub>12</sub> can be absorbed and transported by fluid diffusion. Doctors traditionally believed that the main reasons of vitamin B<sub>12</sub> deficiency were that the patients were lacking intrinsic factor or had gastrointestinal disease or bowel resection. Gastrointestinal absorption barriers of vitamin B<sub>12</sub> can be avoided by intramuscular injection.

The mechanism for the oral route is most probably that free vitamin B<sub>12</sub> can be absorbed both passively (without binding to intrinsic factor) as well as actively (following binding to intrinsic factor) in the terminal ileum. Passive diffusion accounts for 1.2% of total absorption with a bioavailability unaffected in people with pernicious anaemia or gastro-duodenal surgical resection (Berlin 1968; Berlin 1978). High doses of oral vitamin B<sub>12</sub> (e.g. 1000 µg daily) may be able to produce adequate absorption of vitamin B<sub>12</sub> even in the presence of intrinsic factor deficiency, and therefore may be an alternative to the intramuscular route for many people.

### Why it is important to do this review

This review is an update of the Cochrane Review comparing oral with intramuscular vitamin B<sub>12</sub> published in 2005 (Vidal-Alaball 2005). The original review suggested that high doses of oral vitamin B<sub>12</sub> may be as effective as intramuscular administration in obtaining short-term haematological and neurological responses in vitamin B<sub>12</sub>-deficient people.

Intramuscular injections are a “considerable source of work” for healthcare professionals, mainly general practitioners and community nurses (Middleton 1985). There is little difference in the cost of oral versus intramuscular therapy when the medication alone is considered. However, intramuscular administration often involves a special trip to a health facility or a home visit by a health professional to administer the injection (Houle 2014). Oral treatment could therefore save considerable health service resources.

A recent Canadian study estimated that converting people aged over 65 years on B<sub>12</sub> replacement from the intramuscular to oral

form could save CAD 13,975,883, even if no additional physician visits were billed for people receiving intramuscular therapy. A total of CAD 8,444,346 could be saved from reduced administration costs alone over five years (Houle 2014).

## OBJECTIVES

To assess the effects of oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency.

## METHODS

### Criteria for considering studies for this review

#### Types of studies

We included randomised controlled clinical trials examining the use of oral versus intramuscular vitamin B<sub>12</sub> to treat vitamin B<sub>12</sub> deficiency. We regarded a two-week treatment duration as minimum trial duration.

We excluded trials examining the role of vitamin B<sub>12</sub> in the prevention of cardiovascular diseases, because the dose of vitamin B<sub>12</sub> used in those trials may be different from the dose used to treat vitamin B<sub>12</sub> deficiency, and the majority of participants included in such trials are not vitamin B<sub>12</sub> deficient.

#### Types of participants

Trial participants with vitamin B<sub>12</sub> deficiency, meeting criteria for vitamin B<sub>12</sub> replacement therapy.

#### Diagnostic criteria for vitamin B<sub>12</sub> deficiency

We used a cut-off point of below 200 pg/mL (below 148 pmol/L) as a threshold serum level for vitamin B<sub>12</sub> deficiency.

#### Excluded populations

We excluded trials with participants with:

- primary folate deficiency, because the concomitant use of folate might confound the metabolic outcome measures;
- end-stage renal disease or on haemodialysis, because renal disease might confound the metabolic outcome measures.

#### Types of interventions

##### Intervention

- Oral vitamin B<sub>12</sub>

## Comparator

- Intramuscular vitamin B<sub>12</sub>

Where a trial included multiple arms, we included any arm that met the inclusion criteria of our review.

## Minimum duration of intervention

We defined minimum trial duration as two weeks, and only included trials with interventions that lasted longer than two weeks. We planned to list trials with less than two weeks duration in an Additional table but not include them in the analyses, however we did not encounter any such trials.

## Types of outcome measures

We analysed the following outcomes in the review, but did not use them as a basis for including or excluding studies. Had we found relevant trials not reporting any of our primary or secondary outcomes, we would have included the trials but we would not have evaluated them in detail.

## Primary outcomes

1. Serum vitamin B<sub>12</sub> levels.
2. Clinical signs and symptoms of vitamin B<sub>12</sub> deficiency.
3. Adverse events.

## Secondary outcomes

1. Health-related quality of life.
2. Acceptability.
3. Haemoglobin and mean corpuscular volume (MCV).
4. Total homocysteine and serum methylmalonic acid levels.
5. Socioeconomic effects.

## Method and timing of outcome measurement

All outcomes required a minimum of two weeks follow-up from baseline. We categorised the time points of outcome measurement as short term (two weeks to three months), medium term (three to nine months), and long term (more than nine months).

- Serum vitamin B<sub>12</sub> levels: measured at the end of study (mean values and whether these were normalised; normalised serum vitamin B<sub>12</sub> was defined as > 240 pg/mL).
- Clinical signs and symptoms of vitamin B<sub>12</sub> deficiency: e.g. fatigue, macrocytosis, pancytopenia, depression, tiredness, paralysis, dementia psychosis measured at short, medium, and long term.
- Adverse events: e.g. itching, exanthema, chills, fever, hot flushes, nausea, dizziness, and anaphylaxis and measured at short, medium, and long term.
- Health-related quality of life: evaluated by a validated instrument such as 36-item Short Form Health Survey (SF-36) and measured at short, medium, and long term.

- Acceptability: acceptability to participants as defined by trial authors and measured at short, medium, and long term.
- Haemoglobin and MCV: measured at short, medium, and long term.
- Total homocysteine and serum methylmalonic acid levels: measured at short, medium, and long term.
- Socioeconomic effects: refer to costs and measured at short, medium, and long term.

## Summary of findings

We presented a 'Summary of findings' table reporting the following outcomes, listed according to priority.

1. Serum vitamin B<sub>12</sub> levels.
2. Clinical signs and symptoms of vitamin B<sub>12</sub> deficiency (such as depression, tiredness, paralysis, or dementia).
3. Adverse events.
4. Health-related quality of life.
5. Acceptability.
6. Socioeconomic effects.

## Search methods for identification of studies

### Electronic searches

We searched the following sources between the specified dates and placed no restrictions on the language of publication.

- Cochrane Library
  - Cochrane Central Register of Controlled Trials (CENTRAL) (2005 to issue 6 of 12, June 2017; search date 17 July 2017)
  - Database of Abstracts of Reviews of Effects (DARE) (2005 to issue 2 of 4, April 2015; search date 22 July 2015)
  - Health Technology Assessment Database (2005 to issue 2 of 4, April 2015; search date 22 July 2015)
  - NHS Economic Evaluation Database (2005 to issue 2 of 4, April 2015; search date 22 July 2015)
- Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to present> (1 December 2014 to 17 July 2017)
- Embase <1974 to 2016 November 09> (2004 Week 48 to 10 November 2016)
- LILACS (Latin American and Caribbean Health Sciences Literature database) (<last update 27 October 2006>) (Inception to 10 November 2016)
- ClinicalTrials.gov ([clinicaltrials.gov](http://clinicaltrials.gov)) (search date 17 July 2017)
- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ([apps.who.int/trialsearch/](http://apps.who.int/trialsearch/)) (search date 10 November 2016)

We continuously applied a MEDLINE (via Ovid) email alert service established by the Cochrane Metabolic and Endocrine Disorders (CMED) Group to identify newly published studies using the same search strategy as described for MEDLINE (for details on search strategies, see [Appendix 1](#)).

### **Searching other resources**


We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of retrieved included trials, systematic reviews, meta-analyses, and health technology assessment reports. In addition, we contacted authors of included trials to identify any further published or unpublished trials and ongoing trials that we may have missed.

## **Data collection and analysis**

### **Selection of studies**

For this update, two review authors (HYW and THL) independently scanned the abstract or title, or both, of every record retrieved, to determine which studies should be assessed further. We investigated the full-text articles of all potentially relevant articles. Any discrepancies were resolved through consensus or by recourse to a third review author (YNS). If we could not resolve a disagreement, we categorised the study as a 'study awaiting classification' and contacted the study authors for clarification. We have presented an adapted PRISMA flow diagram to show the process of study selection ([Figure 1](#)) ([Liberati 2009](#)).

**Figure 1. Study flow diagram.**



### Data extraction and management

For trials that fulfilled the inclusion criteria, two review authors (LYL and LLQ) independently extracted key participant and intervention characteristics and outcomes. We included key characteristics of the trials, such as trial design, setting, sample size, population, and how outcomes were defined or collected in the trials. In addition, we also collected data on the method of diagnosing vitamin B<sub>12</sub> deficiency, any pre-existing treatment and titration period.

We reported data on efficacy outcomes and adverse events using standard data extraction templates supplied by the CMED Group (for details see [Characteristics of included studies](#); [Table 1](#); [Appendix 2](#); [Appendix 3](#); [Appendix 4](#); [Appendix 5](#); [Appendix 6](#); [Appendix 7](#); [Appendix 8](#); [Appendix 9](#); [Appendix 10](#)). Any disagreements were resolved by discussion or, if required, by consultation with a third review author (YNS).

We provided information about potentially relevant ongoing studies, including the trial identifier number, in the [Characteristics of ongoing studies](#) and in [Appendix 5](#) (matrix of trial endpoints (publications and trial documents)). We attempted to find the protocol for each included study and reported primary, secondary, and other outcomes in comparison with data in publications in [Appendix 5](#).

We emailed all authors of the included trials to enquire whether they would be willing to answer questions regarding their trials. [Appendix 11](#) shows the results of this survey. Thereafter, when required, we sought relevant missing information on the trial from the primary author(s) of the article.

### Dealing with duplicate and companion publications

In the event of duplicate publications, companion documents, or multiple reports of a primary study, we planned to maximise the information yield by collating all available data and using the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, or multiple reports of a primary trial as secondary references under the study ID of the included or excluded trial.

### Data from clinical trial registers

In cases where the data of included trials were available as study results in clinical trial registers such as ClinicalTrials.gov or similar sources, we planned to make full use of this information and used this to extract data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial register but no additional information was available, we added this trial to the [Characteristics of studies awaiting classification](#) table.

### Assessment of risk of bias in included studies

Two review authors (LYL and LLQ) independently assessed the risk of bias of each included study. Any disagreements were resolved by consensus, or by consultation with a third review author (YNS). If adequate information was not available from the publications or trial protocols, we contacted trial authors for missing data on 'Risk of bias' items. We contacted authors of included studies but not due to inadequate information on 'Risk of bias' items.

Using the Cochrane 'Risk of bias' assessment tool ([Higgins 2011a](#); [Higgins 2011b](#)), we judged 'Risk of bias' criteria as having either low, high, or unclear risk, evaluating the individual bias items described in the *Cochrane Handbook for Systematic Reviews of Interventions* according to the criteria and associated categorisations contained therein ([Higgins 2011a](#)).

### Random sequence generation (selection bias due to inadequate generation of a randomised sequence) - assessment at trial level

For each included trial we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.

- Low risk of bias: the sequence generation was achieved using computer-generated random numbers or a random numbers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial. We considered the use of the minimisation technique as equivalent to being random.
- Unclear risk of bias: insufficient information about the sequence generation process.
- High risk of bias: the sequence generation method was non-random or quasi-random (e.g. sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number; allocation by judgement of the clinician; allocation by preference of the participant; allocation based on the results of a laboratory test or a series of tests; allocation by availability of the intervention).

### Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment) - assessment at trial level

For each included trial we described the method used to conceal allocation to interventions prior to assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment.

- Low risk of bias: central allocation (including telephone, interactive voice-recorder, web-based, and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.

- Unclear risk of bias: insufficient information about the allocation concealment.

- High risk of bias: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

**Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by participants and personnel during the trial) - assessment at outcome level**

We evaluated the risk of detection bias separately for each outcome (Hróbjartsson 2013). We noted whether endpoints were self reported, investigator assessed, or adjudicated outcome measures (see below).

- Low risk of bias: blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken; no blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding.

- Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the trial did not address this outcome.

- High risk of bias: no blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of trial participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.

**Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment) - assessment at outcome level**

We evaluated the risk of detection bias separately for each outcome (Hróbjartsson 2013). We noted whether endpoints were self reported, investigator assessed, or adjudicated outcome measures (see below).

- Low risk of bias: blinding of outcome assessment ensured, and unlikely that the blinding could have been broken; no blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding.

- Unclear risk of bias: insufficient information about the blinding of outcome assessors; the trial did not address this outcome.

- High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.

**Incomplete outcome data (attrition bias due to amount, nature, or handling of incomplete outcome data) - assessment at outcome level**

For each included trial and for each outcome, we described the completeness of data, including attrition and exclusions from the analysis. We stated whether trials reported attrition and exclusions, and the number of participants included in the analysis at each stage (compared with the number of randomised participants per intervention/comparator groups). We also noted if trials reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to outcomes. We considered the implications of missing outcome data per outcome, such as high dropout rates (e.g. above 15%) or disparate attrition rates (e.g. difference of 10% or more between trial arms).

- Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes not enough to have a clinically relevant impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data.

- Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias; the trial did not address this outcome.

- High risk of bias: reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (mean difference or standardised mean difference) among missing outcomes enough to induce clinically relevant bias in observed effect size; 'as-treated' or similar analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.



### Selective reporting (reporting bias due to selective outcome reporting) - assessment at trial level

We assessed outcome reporting bias by integrating the results of Appendix 5 'Matrix of trial endpoints (publications and trial documents)' (Boutron 2014; Mathieu 2009), with those of Appendix 6 'High risk of outcome reporting bias according to Outcome Reporting Bias In Trials (ORBIT) classification' (Kirkham 2010). This analysis formed the basis for the judgement of selective reporting.

- Low risk of bias: the trial protocol was available, and all of the trial's prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way; the study protocol is not available, but it was clear that the published reports include all expected outcomes (ORBIT classification).
- Unclear risk of bias: insufficient information about selective reporting.
- High risk of bias: not all of the trial's prespecified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the trial report fails to include results for a key outcome that would be expected to have been reported for such a trial (ORBIT classification).

### Other bias (bias due to problems not covered elsewhere) - assessment at trial level

- Low risk of bias: the trial appeared to be free of other sources of bias.
- Unclear risk of bias: insufficient information to assess whether an important risk of bias existed; insufficient rationale or evidence that an identified problem introduced bias.
- High risk of bias: had a potential source of bias related to the specific trial design used; has been claimed to have been fraudulent; had some other serious problem.

We have presented a 'Risk of bias' graph and a 'Risk of bias' summary figure.

We distinguished between self reported, investigator-assessed, and adjudicated outcome measures.

We defined the following outcomes as self reported.

- Clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, as reported by participants.
- Health-related quality of life.
- Acceptability.
- Adverse events, as measured by participants.

We defined the following outcomes as investigator-assessed outcome.

- Clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, as reported by study personnel.
- Haemoglobin and MCV.
- Total homocysteine and serum methylmalonic acid levels.
- Adverse events, as measured by study personnel.
- Socioeconomic effects.

### Summary assessment of risk of bias

**Risk of bias for a trial across outcomes:** some 'Risk of bias' domains like selection bias (sequence generation and allocation sequence concealment) affect the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, we planned to mark all endpoints investigated in the associated trial as high risk. Otherwise, we would not perform a summary assessment of the risk of bias across all outcomes for a trial.

**Risk of bias for an outcome within a trial and across domains:** we planned to assess the risk of bias for an outcome measure including all of the entries relevant to that outcome (i.e. both trial-level entries and outcome-specific entries). We considered low risk of bias to denote a low risk of bias for all key domains; unclear risk to denote an unclear risk of bias for one or more key domains; and high risk to denote a high risk of bias for one or more key domains.

**Risk of bias for an outcome across trials and across domains:** these are our main summary assessments which we would incorporate in our judgements about the quality of evidence in the 'Summary of findings table 1'. We defined outcomes as at low risk of bias when most information came from trials at low risk of bias; unclear risk when most information came from trials at low or unclear risk of bias; and high risk when a sufficient proportion of information came from trials at high risk of bias.

### Measures of treatment effect

When at least two studies were available for a comparison and a given outcome, we expressed dichotomous data as odds ratio (OR) or risk ratio (RR) with 95% confidence interval (CI). We expressed continuous data as mean difference (MD) with 95% CIs. We planned to express time-to-event data as hazard ratio (HR) with 95% CI, however we did not encounter this type of data.

### Unit of analysis issues

We planned to take into account the level at which randomisation occurred, such as cross-over trials, cluster-randomised trials, and multiple observations for the same outcome.

If more than one comparison from the same trial was eligible for inclusion in the same meta-analysis, we would either combine groups to create a single pair-wise comparison or appropriately reduce the sample size so that the same participants did not contribute multiple times (splitting the 'shared' group into two or more groups). While the latter approach offers some solution to



adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (Higgins 2011a).

### Dealing with missing data

If possible, we obtained missing data from trial authors and carefully evaluated important numerical data such as screened, randomly assigned participants as well as intention-to-treat, as-treated, and per-protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow-up, withdrawals) and critically appraised issues concerning missing data and imputation methods (e.g. last observation carried forward).

In trials where the standard deviation (SD) of the outcome was not available at follow-up or could not be re-created, we standardised by the average of the pooled baseline SD from those trials in which this information was reported.

Where trials did not report means and SDs for outcomes, and we could not obtain the needed information from trial authors, we imputed these values by estimating the mean and variance from the median, range, and the size of the sample (Hozo 2005).

We planned to investigate the impact of imputation on meta-analyses by performing sensitivity analyses, and we reported per outcome which trials were included with imputed SDs. However, we eventually did not perform meta-analysis due to significant clinical heterogeneity.

### Assessment of heterogeneity

We planned to identify heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard  $\chi^2$  test with a significance level of  $\alpha = 0.1$ . In view of the low power of this test, we also planned to consider the  $I^2$  statistic, which quantifies inconsistency across studies to assess the impact of heterogeneity on the meta-analysis (Higgins 2002; Higgins 2003); an  $I^2$  statistic of 75% or more indicates a considerable level of heterogeneity (Higgins 2011a).

When we found heterogeneity, we attempted to determine potential reasons for it by examining individual study and subgroup characteristics.

In the event of substantial clinical, methodological, or statistical heterogeneity, we did not report study results as meta-analytically pooled effect estimates.

### Assessment of reporting biases

Had we included 10 or more trials investigating a particular outcome, we would have used funnel plots to assess small-study effects. Several explanations may account for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence bias of small trials), and publication bias, therefore we would have interpreted the results carefully (Sterne 2011).

### Data synthesis

Unless good evidence showed homogeneous effects across studies, we primarily summarised data at low risk of bias using a random-effects model (Wood 2008). We interpreted random-effects meta-analyses with consideration of the whole distribution of effects, ideally by presenting a prediction interval (Higgins 2009). A prediction interval specifies a predicted range for the true treatment effect in an individual study (Riley 2011). For rare events such as event rates below 1%, we used Peto's odds ratio method, provided there was no substantial imbalance between intervention and comparator group sizes, and intervention effects were not exceptionally large. In addition, we also performed statistical analyses according to the statistical guidelines presented in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011a).

If in the future adequate data become available, we will use this method of analysis.

### Quality of the evidence

We rated the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity, such as directness of results. Two review authors (HYW and THL) independently rated the quality of the evidence for each outcome. We have presented a summary of the evidence in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies, numbers of participants and studies addressing each important outcome, and rating of overall confidence in effect estimates for each outcome.

We selected six important outcomes and created the [Summary of findings for the main comparison](#) based on methods described in the *Cochrane Handbook for Systematic Reviews of Interventions*, by means of the table editor in Review Manager 5, including [Appendix 12](#) 'Checklist to aid consistency and reproducibility of GRADE assessments' to help with standardisation of the 'Summary of findings' table (Higgins 2011a; Meader 2014; RevMan 2014; Schünemann 2011). As meta-analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the quality of studies using footnotes, and we made comments to aid the reader's understanding of the review where necessary.

### Subgroup analysis and investigation of heterogeneity

We expected the following characteristics to introduce clinical heterogeneity, and planned to carry out the following subgroup analysis with investigation of interactions. If in the future adequate data become available, we will conduct this method of analysis.

- Newly diagnosed participants.

- Participants already established on intramuscular treatment.
- Participants over 65 years of age.
- Participants who have had stomach or small bowel

resection.

- Vegetarians.
- Participants taking anti-ulcer medication over long periods.
- Participants with dementia.
- Participants with AIDS.

### Sensitivity analysis

We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following.

- Published trials.
- Taking into account risk of bias, as specified in the [Assessment of risk of bias in included studies](#) section.
  - Very long or large trials, to establish the extent to which they dominate the results.
  - Trials using the following filters: diagnostic criteria, imputation, language of publication, source of funding (industry versus other), or country.

We also planned to test the robustness of results by repeating the analyses using different measures of effect size (RR, OR, etc.) and different statistical models (fixed-effect and random-effects models). If in the future adequate data become available, we will conduct this method of analysis.

## RESULTS

### Description of studies

For a detailed description of trials, see [Table 1](#), [Characteristics of included studies](#), [Characteristics of excluded studies](#), [Characteristics of ongoing studies](#), and [Studies awaiting classification](#).

### Results of the search

The updated search identified 2328 records, of which 39 full-text articles and records were identified for further examination. We excluded the publications/records based on their titles or abstracts, because they did not meet the inclusion criteria or were not relevant to the question under study (see [Figure 1](#)). After screening the full texts of the selected publications/records, six trials met the inclusion criteria with two ongoing trials ([EUCTR 2009-014468-20-AT](#); [NCT01476007](#)), and one trial awaiting assessment ([Ashok 2011](#)). As two trials, [Bolaman 2003](#) and [Kuzminski 1998](#), have been included in the previous version of this review ([Vidal-Alaball 2005](#)), a total of three trials were included in this update ([Bolaman](#)

[2003](#); [Kuzminski 1998](#); [Saraswathy 2012](#)). We sought additional information from the trial authors but did not receive a response.

### Handsearching

Searching the bibliographies of the selected articles and other relevant publications did not identify additional trials.

### Included studies

A detailed description of the characteristics of included trials is presented elsewhere (see [Characteristics of included studies](#) and [Appendix 2](#); [Appendix 3](#); [Appendix 4](#)). The following is a succinct overview.

### Trial design

All included trials were parallel randomised controlled trials. Two trials had a superiority design ([Bolaman 2003](#); [Kuzminski 1998](#)), and one trial was a non-inferiority study ([Saraswathy 2012](#)). One trial was multicentre study conducted at four centres ([Kuzminski 1998](#)). Two trials had an open-label design ([Bolaman 2003](#); [Saraswathy 2012](#)), and one trial did not report on blinding conditions ([Kuzminski 1998](#)).

One trial was conducted between 2009 to 2010 ([Saraswathy 2012](#)). Two trials were performed more than 10 years ago: from 1993 to 1996 in [Kuzminski 1998](#) and from 1999 to 2003 in [Bolaman 2003](#). The treatment duration and follow-up period ranged between three and four months ([Table 1](#)). No trial was terminated early.

### Settings

The three trials were conducted in South India ([Saraswathy 2012](#)), Turkey ([Bolaman 2003](#)), and the USA ([Kuzminski 1998](#)). Recruiting and treating participants occurred in tertiary care hospitals and ambulatory care centres.

### Participants

For detailed characteristics of participants, please refer to [Appendix 3](#) and [Appendix 4](#).

The trials randomised a total of 153 participants. Ten participants in [Bolaman 2003](#) left the trial early, and five participants in [Kuzminski 1998](#) were judged to have primary folate deficiency rather than cobalamin deficiency and were excluded from the final analysis. Eleven participants in [Saraswathy 2012](#) left the study early due to adverse events (n = 2), loss to follow-up (n = 6), lack of subjective improvement (n = 2), and “expired” (n = 1). Finally, 142 participants completed the three trials (92.8%).

Only one trial reported the ethnicity of participants ([Kuzminski 1998](#)).

No trials reported the duration of vitamin B<sub>12</sub> deficiency.

### Diagnostic criteria

Two trials included people with a serum vitamin B<sub>12</sub> level of less than 160 pg/mL (Bolaman 2003; Kuzminski 1998); the other trial used a threshold of less than 200 pg/mL.

### Inclusion and exclusion criteria

Two trials excluded people with folate deficiency (Bolaman 2003; Kuzminski 1998). One trial excluded people who were already on vitamin B<sub>12</sub> supplements (Saraswathy 2012). The details of inclusion and exclusion criteria in individual trials are outlined in [Characteristics of included studies](#).

### Gender distribution

We could ascertain the overall gender distribution of the 153 participants: 56% were male and 44% were female.

### Age distribution

The mean age of participants ranged from 38.6 to 72 years. Kuzminski 1998 investigated participants with a mean age of 72 years for the oral group and 71 years for the intramuscular (IM) group. Bolaman 2003 investigated participants with a mean age of 60 years for the oral group and 64 years for the IM group. Saraswathy 2012 investigated a younger population group with an average age of 38.6 in the oral vitamin B<sub>12</sub> group and 44.3 in the IM vitamin B<sub>12</sub> group.

### Comorbidities

In one trial 74% of participants had conditions that could have been associated with malabsorption from the gut (including seven people with pernicious anaemia and three people with ileal resection), although it appears that people with inflammatory bowel disease and celiac disease were not included (Kuzminski 1998). One trial included 50% of participants with conditions affecting the ileum that could have been associated with malabsorption from the gut (Bolaman 2003). It appears that people with inflammatory bowel disease and celiac disease were not included. One trial did not report the comorbidities of participants (Saraswathy 2012).

### Interventions

All trials compared oral vitamin B<sub>12</sub> with IM vitamin B<sub>12</sub> (see [Appendix 2](#)).

The total daily dosage of vitamin B<sub>12</sub> in the oral group was 1000 µg, in Bolaman 2003 and Saraswathy 2012, or 2000 µg, in Kuzminski 1998. Bolaman 2003 used cyanocobalamin mixed with 20 mL fruit juice, while Kuzminski 1998 used vitamin B<sub>12</sub> tablets. Saraswathy 2012 did not report details about the administration

of oral vitamin B<sub>12</sub>. The type of vitamin B<sub>12</sub> injection used in two studies was cyanocobalamin (Bolaman 2003; Kuzminski 1998), while the third study did not report this information. However, the treatment duration, frequency, and total dose of vitamin B<sub>12</sub> varied between trials.

- Bolaman 2003 used the same dose of vitamin B<sub>12</sub> and the same frequency of treatment in both arms. The total dose of vitamin B<sub>12</sub> in the three-month trial was 15 mg in each group.
- Kuzminski 1998 used a substantially higher daily and total dose in the oral group (2000 µg per day for four months; total dose 240 mg), while for the IM group, the total dose of vitamin B<sub>12</sub> was merely 9 mg over 90 days.
- Saraswathy 2012 used 1000 µg of vitamin B<sub>12</sub> daily for 3 months in the oral group (total dose 90 mg) and a total dose of 15 mg vitamin B<sub>12</sub> over 9 weeks in the IM group.

### Outcomes

One trial explicitly stated a primary endpoint in the abstract (Saraswathy 2012). The total number of measured outcomes in the included trials ranged from two to nine. All trials described definitions of outcomes in the publications, if applicable ([Appendix 5](#); [Appendix 6](#); [Appendix 7](#)).

### Trials reporting our primary outcomes

Serum vitamin B<sub>12</sub>: two trials measured the mean values of serum vitamin B<sub>12</sub> (Bolaman 2003; Kuzminski 1998). Two trials reported the number of participants with normalisation of serum vitamin B<sub>12</sub> deficiency (Kuzminski 1998; Saraswathy 2012), but the definitions used varied between trials.

- Clinical signs and symptoms of vitamin B<sub>12</sub> deficiency: no trials reported this outcome. Bolaman 2003 stated measuring the “improvements in signs and symptoms of anemia”, however the authors did not report data for this outcome ([Appendix 6](#)).
- Adverse events: two trials reported on adverse events (Bolaman 2003; Saraswathy 2012).

### Trials reporting our secondary outcomes

- Health-related quality of life: no trial reported this outcome.
- Acceptability: no trial reported this outcome.
- Haemoglobin and MCV: Bolaman 2003 (60 participants) reported haemoglobin levels. Two trials (93 participants) reported MCV (Bolaman 2003; Kuzminski 1998).
- Total homocysteine and serum methylmalonic acid levels: one trial (33 participants) reported this outcome (Kuzminski 1998).
- Socioeconomic effects: Bolaman 2003 (60 participants) reported on the tolerability of medication (assessed by a haematologist and patient interviews), and costs, which the trial authors assessed using cost of the trial drug and the injections.

### Other outcomes reported in the included trials

- Mini-Mental State Examination.
- Neurologic symptoms.
- Serum holotranscobalamin levels.
- Serum folate.
- Parietal and intrinsic factor antibodies.
- Serum anti-intrinsic factor antibodies.

### Funding and conflicts of interest in trials

No funding information was reported.

### Excluded studies

We excluded 31 full-text records. The most common reason for exclusion was a non-randomised trial design, or the comparison or population in the trial did not meet intervention criteria. Reasons for exclusion of studies are detailed in [Characteristics of excluded studies](#).

### Ongoing studies


We found two ongoing randomised controlled trials. One trial with an estimated sample size of 320 was registered on ClinicalTrials.gov and was expected to be completed by the year 2017 ([NCT01476007](#)). This trial compared oral vitamin B<sub>12</sub> with IM vitamin B<sub>12</sub> in elderly people (65 years and above) with vitamin deficiency (defined as serum vitamin B<sub>12</sub> less than 179 pg/mL). Another trial was registered on the European Clinical Trials Register in 2010 ([EUCTR 2009-014468-20-AT](#)). This trial compared sublingual vitamin B<sub>12</sub> supplementation with IM vitamin B<sub>12</sub> supplementation after gastric bypass surgery. No further details were reported.

### Risk of bias in included studies

For details on the risk of bias of the included studies see [Characteristics of included studies](#).

For an overview of review authors' judgements about each 'Risk of bias' item for individual studies and across all studies see [Figure 2](#) and [Figure 3](#).

**Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (blank cells indicate that the particular outcome was not measured in some studies).**



**Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study (blank cells indicate that the study did not measure that particular outcome).**

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): adverse events	Blinding of participants and personnel (performance bias): acceptability	Blinding of participants and personnel (performance bias): clinical signs and symptoms of vitamin B12 deficiency	Blinding of participants and personnel (performance bias): haemoglobin and mean corpuscular volume (MCV)	Blinding of participants and personnel (performance bias): health-related quality of life	Blinding of participants and personnel (performance bias): serum vitamin B12 levels	Blinding of participants and personnel (performance bias): socioeconomic effects	Blinding of participants and personnel (performance bias): total homocysteine and serum methylmalonic acid levels	Blinding of outcome assessment (detection bias): adverse events	Blinding of outcome assessment (detection bias): acceptability	Blinding of outcome assessment (detection bias): clinical signs and symptoms of vitamin B12 deficiency	Blinding of outcome assessment (detection bias): haemoglobin and mean corpuscular volume (MCV)	Blinding of outcome assessment (detection bias): health-related quality of life	Blinding of outcome assessment (detection bias): serum vitamin B12 levels	Blinding of outcome assessment (detection bias): socioeconomic effects	Blinding of outcome assessment (detection bias): total homocysteine and serum methylmalonic acid levels	Incomplete outcome data (attrition bias): adverse events	Incomplete outcome data (attrition bias): acceptability	Incomplete outcome data (attrition bias): clinical signs and symptoms of vitamin B12 deficiency	Incomplete outcome data (attrition bias): haemoglobin and mean corpuscular volume (MCV)	Incomplete outcome data (attrition bias): health-related quality of life	Incomplete outcome data (attrition bias): serum vitamin B12 levels	Incomplete outcome data (attrition bias): socioeconomic effects	Incomplete outcome data (attrition bias): total homocysteine and serum methylmalonic acid levels	Selective reporting (reporting bias)	Other bias	
Bolaman 2003	?	?	●			●	●	●		●			●	●	●								?		?	?	?	?	●
Kuzminski 1998	●	?			●		●		●				●	●								●		●	●	●	●	?	●
Saraswathy 2012	?	?	●				●	●						●	●										●	●	●	?	●

### Allocation

We rated one trial as at low risk of bias for randomisation: [Kuzminski 1998](#) stated that they used a statistical package for randomisation. We rated the other two trials as at unclear risk of bias: [Bolaman 2003](#) stated that participants were randomised using the block randomisation method, but did not state how the randomisation was performed. [Saraswathy 2012](#) did not report how the randomisation was conducted.

No trial reported adequate details of allocation concealment. Baseline characteristics were balanced between the two intervention groups for all included trials.

### Blinding

Participants in two trials were not blinded, as the design was open-label randomised controlled trial ([Bolaman 2003](#); [Saraswathy 2012](#)). The other trial did not report sufficient information about blinding procedures ([Kuzminski 1998](#)). However, we judged the

performance bias and detection bias as low risk due to the objective nature of outcome measurements other than the outcome adverse events, which was judged as high risk.

### Incomplete outcome data

In [Kuzminski 1998](#), 38 participants were randomised, but five participants (13%) were excluded from the final analysis because they were judged to have primary folate deficiency rather than vitamin B<sub>12</sub> deficiency. As the missing data were not likely to impact the effect, we assessed attrition bias as low risk.

In [Bolaman 2003](#), 70 participants were enrolled in the study, but 10 (14%) were excluded because of failure to appear at follow-up. The final analysis included 26 participants in the oral group and 34 randomised to receive intramuscular treatment. The authors did not analyse data according to the intention-to-treat principle. We assessed the attrition bias as unclear risk.



In [Saraswathy 2012](#), 60 participants were randomised, but 11 participants (18.3%) left the study early due to various reasons: eight participants dropped out from the oral vitamin B<sub>12</sub> group due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2); three participants from the IM vitamin B<sub>12</sub> group left the study early due to expired (n = 1) and loss to follow-up (n = 2). The attrition rate was high, and the missing data were likely to impact the estimate of effects. We therefore assessed attrition bias as high risk.

### Selective reporting

No trial reported any information about their protocols, therefore it was difficult to judge what outcomes were measured but not reported ([Appendix 5](#)). We assessed reporting bias at trial level as unclear risk. Three outcomes predefined in our protocol were not reported by any of the included trials: i) clinical signs and symptoms of vitamin B<sub>12</sub> deficiency; ii) health-related quality of life; and iii) acceptability. Details about which outcomes were reported by the original trials can be found in [Appendix 6](#).

### Other potential sources of bias

We did not identify other obvious bias in the three included trials and rated this domain as low risk.

### Sample size calculation

Only one trial provided a sample size calculation ([Saraswathy 2012](#)). The calculation was based on the assumption that an equal response of 90% between oral and IM vitamin B<sub>12</sub> groups and a non-inferiority margin of 25% (alpha = 0.25, 1 - beta = 0.80). The expected sample size in each group was 23.

### Effects of interventions

See: [Summary of findings for the main comparison Oral versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency](#)

### Baseline characteristics

For details of baseline characteristics, see [Appendix 3](#) and [Appendix 4](#). Due to the small number of included trials and substantial clinical heterogeneity, instead of pooling the data we primarily presented the extracted data in the forest plots and reported the results descriptively.

### Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub>

#### Primary outcomes

### Serum vitamin B<sub>12</sub> levels

Two trials reported serum vitamin B<sub>12</sub> levels ([Bolaman 2003](#); [Kuzminski 1998](#)). For a detailed description of the interventions, see [Appendix 2](#). The overall quality of the evidence was low due to serious imprecision.

One trial used an oral or IM vitamin B<sub>12</sub> dose of 1000 µg per day and a total dose of 15 mg within three months of treatment ([Bolaman 2003](#)). The oral treatment compared with the IM treatment showed a mean difference (MD) of -11.7 pg/mL (95% confidence interval (CI) -29.5 to 6.1; P = 0.20; 60 participants; [Analysis 1.1](#)) ([Bolaman 2003](#)). After three months, the mean serum vitamin B<sub>12</sub> concentration in the oral vitamin B<sub>12</sub> group was 213.8 pg/mL compared with 225.5 pg/mL in the IM group (normal value: above 300 pg/mL).

Another trial compared an oral vitamin B<sub>12</sub> dose of 2000 µg per day for 120 days (total dose 240 mg) with an IM vitamin B<sub>12</sub> dose of 1000 µg per day over a period of 90 days (total dose 9 mg) ([Kuzminski 1998](#)). The oral compared with the IM treatment showed an MD of 680 pg/mL (95% CI 392.7 to 967.3; P < 0.001; 33 participants; [Analysis 1.1](#)) ([Kuzminski 1998](#)), in favour of oral vitamin B<sub>12</sub>. At four months, the mean serum vitamin B<sub>12</sub> concentration in the oral vitamin B<sub>12</sub> group was 1005 pg/mL (18/18 participants > 300 pg/mL) compared with 325 pg/mL (7/14 participants > 300 pg/mL) in the IM group.

When the normalisation of serum vitamin B<sub>12</sub> was defined as greater than 200 pg/mL, differences between the oral vitamin B<sub>12</sub> and IM vitamin B<sub>12</sub> groups depended on the dose of vitamin B<sub>12</sub> ([Analysis 1.2](#)).

[Saraswathy 2012](#) reported the number of participants achieving normalisation of the serum vitamin B<sub>12</sub> level, defined as ≥ 200 pg/mL ([Saraswathy 2012](#)). The trial employed an oral vitamin B<sub>12</sub> dose of 1000 µg per day for three months (total dose 90 mg) and an IM vitamin B<sub>12</sub> dose of 1000 µg (total dose of 15 mg within three months of treatment). A total of 27/30 in the IM vitamin B<sub>12</sub> group (90%) and 20/30 in the oral vitamin B<sub>12</sub> group (66.7%) achieved this target; although fewer participants in the oral vitamin B<sub>12</sub> group achieved the target, the difference was statistically non-significant ([Analysis 1.2](#)) ([Saraswathy 2012](#)). However, [Kuzminski 1998](#) used a much higher dose of oral vitamin B<sub>12</sub> (240 mg in total) versus a much lower dose of IM vitamin B<sub>12</sub> (total dose 9 mg). A total of 10/14 in the IM vitamin B<sub>12</sub> group (71.4%) and 18/18 in the oral vitamin B<sub>12</sub> group (100%) achieved this target; although more participants in the oral vitamin B<sub>12</sub> group achieved the target, the difference was statistically non-significant ([Analysis 1.2](#)) ([Kuzminski 1998](#)).

### Clinical signs and symptoms

No trial reported this outcome.

### Adverse effects

Two trials reported this outcome (Bolaman 2003; Saraswathy 2012). The overall quality of the evidence was very low due to risk of performance and detection bias and serious imprecision. One trial reported no adverse events in both the oral and IM vitamin B<sub>12</sub> groups (Bolaman 2003). The other trial reported that two participants in the oral vitamin B<sub>12</sub> group left the trial early due to adverse events (Analysis 1.3) (Saraswathy 2012).

### Secondary outcomes

#### Health-related quality of life

No trial reported this outcome.

#### Acceptability to patients

No trial reported this outcome.

### Haemoglobin and mean corpuscular volume

Only one trial reported on haemoglobin measurements (Bolaman 2003). There was no substantial difference between the oral and intramuscular supplementation of vitamin B<sub>12</sub>: MD 0.1 g/dL, 95% CI -0.30 to 0.50; P = 0.63; 60 participants; Analysis 1.4. Two trials reported on MCV measurements (Bolaman 2003; Kuzminski 1998). One trial showed an MD between oral and IM vitamin B<sub>12</sub> treatment of 0.20 fL (95% CI -1.84 to 2.24; P = 0.85; 60 participants; Analysis 1.5) (Bolaman 2003). The other trial reported an MD of -1.00 fL (95% CI -5.80 to 3.80; P = 0.68; 33 participants; Analysis 1.5) (Kuzminski 1998).

### Total homocysteine and serum methylmalonic acid levels

One trial reported on homocysteine measurements. The MD between oral and IM vitamin B<sub>12</sub> treatment was -1.60 μmol/L (95% CI -4.50 to 1.30; P = 0.28; 33 participants; Analysis 1.6) (Kuzminski 1998).

This trial also investigated serum methylmalonic acid. The MD between oral and IM vitamin B<sub>12</sub> treatment was -96 nmol/L (95% CI -200.76 to 8.76; P = 0.07; 33 participants; Analysis 1.7).

### Socioeconomic effects

Only one trial reported the costs of the two administration schemes of vitamin B<sub>12</sub> (Bolaman 2003). The quality of evidence was low due to serious imprecision. The results demonstrated that the costs per treatment were USD 80 per person in the group taking oral vitamin B<sub>12</sub> compared to USD 220 per person in the group using IM vitamin B<sub>12</sub> (P < 0.001). The trial authors did not report which economic analysis was performed.

### Subgroup analyses

We did not perform subgroup analyses due to the small number of included trials and substantial variety among characteristics of population, interventions, and outcome measurements of the included trials. The dosage of orally taken vitamin B<sub>12</sub> might be a potential prognostic factor influencing the treatment effect.

### Sensitivity analyses

Due to substantial clinical heterogeneity and the low number of included trials, we did not pool the data and did not conduct the planned sensitivity analyses.

### Assessment of reporting bias

We did not draw funnel plots due to the limited number of included trials.

## DISCUSSION

### Summary of main results

Low-quality evidence showed that both oral vitamin B<sub>12</sub> and IM vitamin B<sub>12</sub> can improve serum vitamin B<sub>12</sub> levels for people with vitamin B<sub>12</sub> deficiency. However, the dosage of oral vitamin B<sub>12</sub> might be a clinical factor to affect this outcome. When oral vitamin B<sub>12</sub> was used in higher dosages (2000 μg/day with a total dose of 240 mg), the serum vitamin B<sub>12</sub> levels were much higher (on average 680 pg/mL higher) than that in the IM vitamin B<sub>12</sub> group (1000 μg/day with a total dose of 9 mg). Similarly, the number of participants achieving normalisation of vitamin B<sub>12</sub> levels also depended on the dose of vitamin B<sub>12</sub> and was higher in the oral vitamin B<sub>12</sub> group when treated with 2000 μg/day. We found no substantial differences were between the intervention groups for adverse events. There were also no substantial differences between intervention groups in haemoglobin and MCV levels, total homocysteine, and serum methylmalonic acid levels. The costs of treatment in the oral vitamin B<sub>12</sub> group were lower than those in the IM vitamin B<sub>12</sub> group. The overall quality of the evidence was low or very low. Two trials are still ongoing, and the full report of one trial was not published. It is likely that the estimate of the effect may change when data from these trials are included.

Most of the dietary vitamin B<sub>12</sub> is absorbed actively via intrinsic factor, and passive diffusion accounts for about 1% of vitamin B<sub>12</sub> absorption. Therefore, an oral dose of 1000 μg daily should be sufficient to meet the dietary daily amount recommended (Kolber 2014). This theory also explains why higher oral vitamin B<sub>12</sub> can achieve similar effects as intramuscular vitamin B<sub>12</sub>. A previous study confirmed that oral therapy can be effective even in intrinsic



factor-lacking and gastrointestinal-disabled people (Andres 2008; Andres 2009; Andres 2010). Some of the participants in our included trials, such as those with atrophic gastritis, also showed improvements after oral vitamin B<sub>12</sub> therapy. However, these results must be interpreted with caution due to the small number of participants and trials.

## Overall completeness and applicability of evidence

More elderly males with vitamin B<sub>12</sub> deficiency were included in the current review. A higher prevalence of vitamin B<sub>12</sub> deficiency amongst the elderly is documented (Stabler 2013), and vitamin B<sub>12</sub> deficiency occurs more frequently in elderly men than in elderly women. None of the trials was conducted in a primary care setting, where most people with vitamin B<sub>12</sub> deficiencies are treated; this makes generalisation of the results more difficult. It should be noted that one ongoing trial recruiting participants from 23 primary settings may add important information (NCT01476007). Another factor affecting generalisation is that the three included trials used strict and numerous exclusion criteria.

Secondly, for IM interventions, there are two main kinds of vitamin B<sub>12</sub> injections: cyanocobalamin and hydroxocobalamin. Only cyanocobalamin was used in the studies included in this review. It should be noted that the bioavailability of injectable hydroxocobalamin preparations is much higher than the water solution preparations of cyanocobalamin (Boddy 1968; Glass 1961).

Thirdly, the number of outcomes reported was limited, and several important outcomes were not measured in the original trials, such as clinical signs and symptoms of vitamin B<sub>12</sub> deficiency after the intervention. Notably, using the normalisation of serum levels of vitamin B<sub>12</sub> and its metabolites to reflect the response to treatment is not enough. There may be no direct correlation between normalisation of serum vitamin B<sub>12</sub> and improvement of clinical symptoms (Andres 2009; Hall 1977).

## Quality of the evidence

Using GRADE, we judged the quality of the evidence in the review to be low or very low. This was mainly due to serious imprecision, inconsistency between trials, and high risk of bias for some domains of included trials. The body of evidence did not allow robust conclusions regarding the objectives of our review. We could include only three trials with small numbers of participants. Missing data (attrition rates ranged from 13.2% to 18.3%) may also have affected some effects estimates. The inconsistency between trials was associated with substantial clinical heterogeneity.

## Potential biases in the review process

The incomplete correspondence with trial authors and the missing results of the two ongoing trials limit our evidence base. We failed to obtain the full text of one trial (Ashok 2011), in which 38 participants were recruited. The definitions of vitamin B<sub>12</sub> deficiency used in this review differed from that defined in our protocol, in which we used a more strict threshold to define vitamin B<sub>12</sub> deficiency in order to reflect common practice.

## Agreements and disagreements with other studies or reviews

This is an update of a previous review (Vidal-Alaball 2005). We included one additional trial in this update (Saraswathy 2012), but the conclusions remain unchanged. We identified no recent systematic review or health technology assessment report on oral versus IM vitamin B<sub>12</sub> supplement for vitamin B<sub>12</sub> deficiency.

## AUTHORS' CONCLUSIONS

### Implications for practice

Questions about the use of oral or intramuscular (IM) vitamin B<sub>12</sub> have been debated by doctors for nearly 50 years, and a conclusive answer is still lacking. Low-quality evidence indicates that an oral dose of 1000 µg/day vitamin B<sub>12</sub> works similarly to IM vitamin B<sub>12</sub> in restoring serum B<sub>12</sub> levels and acquiring haematological responses in people who are vitamin B<sub>12</sub> deficient. An oral dose of 2000 µg/day vitamin B<sub>12</sub> might be more effective than IM vitamin B<sub>12</sub>.

Adverse events were rare, and low-quality evidence indicates that oral vitamin B<sub>12</sub> costs less than IM vitamin B<sub>12</sub> injections. No trial reported on clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, health-related quality of life, or acceptability of the treatment scheme.

### Implications for research

All of the trials included in our review had methodological shortcomings and an insufficient set of outcome data. Further trials should conduct better blinding procedures, recruit more participants, and provide adequate reporting. In addition, future trials should also measure important outcomes such as the clinical signs and symptoms of vitamin B<sub>12</sub> deficiency, health-related quality of life, and socioeconomic effects. It is also important that the protocol considers adverse effects and that these are reported as part of the trial.

Future trials should be performed in primary care settings on participants without considering gender, ethnicity, age, and region.

It is important for future research to include participants with poor absorption of oral vitamin B<sub>12</sub>, such as those with pernicious anaemia, gastrointestinal disease or resection. Considering that the diagnosis and treatment of vitamin B<sub>12</sub> deficiency is related to the metabolism of vitamin B<sub>12</sub>, more research should be conducted focusing on the absorption, distribution, metabolism, and excretion processes of vitamin B<sub>12</sub>.

## ACKNOWLEDGEMENTS

- Christopher C Butler, Rebecca Cannings-John, Andrew Goringe, Kerry Hood, Andrew McCaddon, Ian McDowell, Alexandra Papaioannou, Johannes C van der Wouden, and Rianne Langeveld (original Cochrane Review).

- The search strategies for this review update were designed and run by the CMED Group's Information Specialist, Maria-Inti Metzendorf.

- We thank Ms Sai Zhao from Systematic Review Solution Ltd for being our methodology and reporting consultant.

## REFERENCES

### References to studies included in this review

#### Bolaman 2003 *{published data only}*

Bolaman Z, Kadikoylu G, Yukselen V, Yavasoglu I, Barutca S, Senturk T. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. *Clinical Therapeutics* 2003; **25**(12):3124–34.

#### Kuzminski 1998 *{published data only}*

Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. *Blood* 1998;**92**(4):1191–8.

#### Saraswathy 2012 *{published data only}*

Saraswathy AR, Dutta A, Simon EG, Chacko A. Randomized open label trial comparing efficacy of oral versus intramuscular vitamin B12 supplementation for treatment of vitamin B12 deficiency. *Gastroenterology* 2012; **142**(5 Suppl 1):S216.

### References to studies excluded from this review

#### Aguilar 2004 *{published data only}*

Aguilar Franco C. Subcutaneous administration of vitamin B12. *Atencion Primaria* 2004;**34**:509 (author reply 509).

#### Andres 2005a *{published data only}*

Andres E, Affenberger S, Vinzio S, Noel E, Kaltenbach G, Schlienger JL. Cobalamin deficiencies in adults: update of etiologies, clinical manifestations and treatment. *Revue de Medecine Interne* 2005;**26**:938–46.

#### Andres 2005b *{published data only}*

Andres E, Noel E, Kaltenbach G. Usefulness of oral vitamin B12 therapy in vitamin B12 deficiency related to food-cobalamin malabsorption: Short and long-term outcome [1]. *European Journal of Internal Medicine* 2005;**16**:218.

#### Andres 2011 *{published data only}*

Andres E, Mecili M. Oral vitamin B12 therapy. *Annals of Surgical Oncology* 2011;**18** Suppl 3:S196-8 (author reply S199).

#### Andres 2012 *{published data only}*

Andres E. Oral cobalamin therapy: It may be perhaps time to propose international recommendations?. *Presse Medicale* 2012;**41**:895–8.

#### Bharath 2015 *{published data only}*

Bharath V, Hsia CC. Vitamin B12 deficiency presenting as pancytopenia with ring sideroblasts. *Blood* 2015;**126**:2255.

#### Bharatwaj 2012 *{published data only}*

Bharatwaj RS. The problem of cyanocobalamin deficiency in a developing country set-up and the possible solutions. *Journal of Clinical and Diagnostic Research* 2012;**6**:921–2.

#### Butler 2006 *{published data only}*

Butler CC, Vidal-Alaball J, Cannings-John R, McCaddon A, Hood K, Papaioannou A, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. *Family Practice* 2006;**23**:279–85.

#### Castelli 2010 *{published data only}*

\* Castelli MC, Friedman K, Sherry J, Brazzillo K, Genoble L, Bhargava P, et al. Comparing the efficacy and tolerability of a new daily oral vitamin B12 formulation and intermittent intramuscular vitamin B12 in normalizing low cobalamin levels: a randomized, open-label, parallel-group study. *Clinical Therapeutics* 2011;**33**:358–71.  
Castelli MC, Wong D, Friedman K, Bhargava P, Riley GM. Normalization of vitamin B12 (B12) levels achieved following 1000 mcg oral Eligen B12 therapy: a clinical study comparing the efficacy and safety of oral B12 therapy versus intramuscular (IM) therapy. *FASEB Journal* 2010; **24**:lb325.

#### Emans 2013 *{published data only}*

Emans ME, Gaillard CAJM, Pfister R, Tanck MW, Boekholdt SM, Wareham NJ, et al. Response to letter by Balta et al. *International Journal of Cardiology* 2013;**169**: 89–94.

#### EUCTR 2013-004835-60 *{published and unpublished data}*

Vitamin deficiencies and supplementation in morbidly obese. <https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-004835-60/NL> (accessed 6 December 2017).

- Geisel 2005** *{published data only}*  
Geisel J, Schorr H, Bodis M, Isber S, Hubner U, Knapp JP, et al. The vegetarian lifestyle and DNA methylation. *Clinical Chemistry & Laboratory Medicine* 2005;**43**:1164–9.
- Haffner 2016** *{published data only}*  
Haffner J. Oral treatment of vitamin B12 deficiency. *Tidsskrift for Den Norske Laegeforening* 2016;**136**:108.
- Houle 2014** *{published data only}*  
Houle SK, Kolber MR, Chuck AW. Should vitamin B12 tablets be included in more Canadian drug formularies? An economic model of the cost-saving potential from increased utilisation of oral versus intramuscular vitamin B12 maintenance therapy for Alberta seniors (Provisional abstract). *BMJ Open* 2014; Vol. 4, issue 5:e004501.
- ISRCTN22063938** *{published and unpublished data}*  
Cobalamin deficiency in primary care: a placebo-controlled, double-blind, randomized trial. <http://www.isrctn.com/ISRCTN22063938> (accessed 6 December 2017).
- Kim 2011** *{published data only}*  
Kim HI, Hyung WJ, Song KJ, Choi SH, Kim CB, Noh SH. Oral vitamin B12 replacement: an effective treatment for vitamin B12 deficiency after total gastrectomy in gastric cancer patients. *Annals of Surgical Oncology* 2011;**18**:3711–7.
- Kolber 2014** *{published data only}*  
Kolber MR, Houle SK. Oral vitamin B12: a cost-effective alternative. *Canadian Family Physician* 2014;**60**:111–2.
- Kripke 2006** *{published data only}*  
Kripke C. Is oral vitamin B12 as effective as intramuscular injection?. *American Family Physician* 2006;**73**:65.
- Leidenmuhler 2013** *{published data only}*  
Shakeri-Leidenmuhler S, Poglitsch M, Kefurt R, Felberbauer FX, Bohdjalian A, Langer FB, et al. Vitamin B12 substitution after gastric bypass surgery: sublingual or intramuscular?. *European Surgery - Acta Chirurgica Austriaca* 2013;**45**(2 Suppl):S4 (O33).
- Leon 2013** *{published data only}*  
Leon CA, Georges P, Zaeeter W. Vitamin B12 deficiency. *New England Journal of Medicine* 2013;**368**:2041.
- Lin 2012** *{published data only}*  
Lin J, Kelsberg G, Safranek S. Clinical inquiry: Is high-dose oral B12 a safe and effective alternative to a B12 injection?. *Journal of Family Practice* 2012;**61**:162–3.
- Lonn 2006** *{published data only}*  
Lonn E. Dr. Lonn replies. *New England Journal of Medicine* 2006;**355**:209–10.
- Masucci 2013** *{published data only}*  
Masucci L, Goeree R. Vitamin B12 intramuscular injections versus oral supplements: a budget impact analysis. *Ontario Health Technology Assessment Series* 2013;**13**:1–24.
- Metaxas 2013** *{published data only}*  
Metaxas C, Schmutz A, Walter P, Hersberger KE. Oral versus parenteral route of application: the patient's preference. *International Journal of Clinical Pharmacy* 2013;**35**(6):1295–6.
- Metaxas 2017** *{published data only}*  
Metaxas C, Mathis D, Jeger C, Hersberger KE, Arnet I, Walter P. Early biomarker response and patient preferences to oral and intramuscular vitamin B12 substitution in primary care: a randomised parallel-group trial. *Swiss Medical Weekly* 2017;**147**:w14421.
- NCT00699478** *{published and unpublished data}*  
Oral vitamin B12 administration for vitamin B12 deficiency after total gastrectomy. <https://clinicaltrials.gov/ct2/show/NCT00699478> (accessed 6 December 2017).
- Pacholok 2013** *{published data only}*  
Pacholok SM. Vitamin B12 deficiency: serious consequences. *Pharmacy Times* 2013;**80**(2):1.
- Radziwill 2014** *{published data only}*  
Radziwill R. Can a vitamin B12 deficiency in PPI intake be offset by an increased intake of oral B12?. *Medizinische Monatsschrift für Pharmazeuten* 2014;**37**:299.
- Schijns 2016** *{published data only}*  
Schijns W, Meer van der L, Deden L, Janssen IMC, Berends FJ, Aarts EO. Efficacy of oral versus intramuscular vitamin B12 supplementation following Roux-en-Y gastric bypass. *Obesity Facts* 2016; Vol. 9, issue Suppl 1:PO3.104.
- Schloss 2015** *{published data only}*  
Schloss J M, Colosimo M, Airey C, Vitetta L. Chemotherapy-induced peripheral neuropathy (CIPN) and vitamin B12 deficiency. *Supportive Care in Cancer* 2015;**23**:1843–50.
- Stabler 2015** *{published data only}*  
Stabler SP. Anemias due to essential nutrient deficiencies. *World Review of Nutrition & Dietetics* 2015;**111**:164–8.

## References to studies awaiting assessment

- Ashok 2011** *{published data only}*  
Chacko A. Is vitamin B12 tablets as effective as vitamin B12 injections for the treatment of vitamin B12 deficiency?. Christian Medical College, Vellore India 2011.

## References to ongoing studies

- EUCTR 2009-014468-20-AT** *{published and unpublished data}*  
A prospective comparison of vitamin B12 supplementation after gastric bypass surgery (sublingual vs. intramuscular). <https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-014468-20/AT> (accessed 6 December 2017).
- NCT01476007** *{published data only}*  
Gerencia de Atención Primaria Madrid. Oral/intramuscular B12 to treat cobalamin deficiency. Instituto de Salud Carlos III 2015.  
Sanz-Cuesta T, González-Escobar P, Riesgo-Fuertes R, Garrido-Elustondo S, del Cura-González I, Martín-Fernández J, et al. Oral versus intramuscular administration of vitamin B12 for the treatment of patients with vitamin B12 deficiency: a pragmatic, randomised, multi-centre, non-inferiority clinical trial undertaken in the primary

- healthcare setting (Project OB12). *BMC Public Health* 2012;**12**:394.
- Área de Investigación. Oral versus intramuscular cobalamin to treat cobalamin deficiency: noninferiority randomised controlled trial, pragmatic and multi-center in the primary healthcare setting (OB12 project). Consorcio de Apoyo a la Investigación Biomédica en red (CAIBER) 2011.
- Additional references**
- Allen 2009**  
Allen L. How common is vitamin B-12 deficiency?. *American Journal of Clinical Nutrition* 2009;**89**:693–6.
- Andres 2004**  
Andres E, Loukili NH, Noel E, Kaltenbach G, Ben Abdelgheni M, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. *Canadian Medical Association Journal* 2004;**171**(3):251–9.
- Andres 2008**  
Andres E, Vogel T, Federici L, Zimmer J, Kaltenbach G. Update on oral cyanocobalamin (vitamin B12) treatment in elderly patients. *Drugs and Aging* 2008;**25**(11):927–32.
- Andres 2009**  
Andres E, Serraj K, Mecili M, Ciobanu E, Vogel T, Weitten T. Update of oral vitamin B12. *Annales d'Endocrinologie* 2009;**70**(6):455–61.
- Andres 2010**  
Andres E, Fothergill H, Mecili M. Efficacy of oral cobalamin (vitamin B12) therapy. *Expert Opinion on Pharmacotherapy* 2010;**11**(2):249–56.
- Anonymous 1991**  
Dietary reference values for food energy and nutrients for the United Kingdom. Report of the panel on dietary reference values of the committee on medical aspects of food policy. Report on Health and Social Subjects 1991; Vol. 41:1–210.
- Bahadır 2015**  
Bahadır A, Reis PG, Erduran E. Oral vitamin B12 treatment is effective for children with nutritional vitamin B12 deficiency. *Journal of Paediatrics and Child Health* 2014;**50**(9):721–5.
- Berlin 1968**  
Berlin H, Berlin R, Brante G. Oral treatment of pernicious anemia with high doses of vitamin B12 without intrinsic factor. *Acta Medica Scandinavica* 1968;**184**(4):247–58.
- Berlin 1978**  
Berlin R, Berlin H, Brante G, Pilbrant A. Vitamin B12 body stores during oral and parenteral treatment of pernicious anaemia. *Acta Medica Scandinavica* 1978;**204**(1-2):81–4.
- BNF 2004**  
British Medical Association, Royal Pharmaceutical Society of Great Britain. *British National Formulary*. 3rd Edition. Vol. 48, London: British Medical Association, 2004:456–7.
- Boddy 1968**  
Boddy K, King P, Mervyn L, Macleod A, Adams JE. Retention of cyanocobalamin, hydroxocobalamin, and coenzyme B 12 after parenteral administration. *Lancet* 1968;**292**(7570):710–2.
- Boutron 2014**  
Boutron I, Altman DG, Hopewell S, Vera-Badillo F, Tannock I, Ravaut P. Impact of spin in the abstracts of articles reporting results of randomized controlled trials in the field of cancer: the SPIIN randomized controlled trial. *Journal of Clinical Oncology* 2014;**32**:4120–6.
- Brito 2015**  
Brito A, Mujica-Coopman MF, López de Romaña D, Cori H, Allen LH. Folate and vitamin B12 status in Latin America and the Caribbean: an update. *Food and Nutrition Bulletin* 2015;**36**(Suppl 2):S109–18. [DOI: 10.1177/0379572115585772]
- Castelli 2011**  
Castelli MC, Friedman K, Sherry J, Brazzillo K, Genoble L, Bhargava P, et al. Comparing the efficacy and tolerability of a new daily oral vitamin B12 formulation and intermittent intramuscular vitamin B12 in normalizing low cobalamin levels: a randomized, open-label, parallel-group study. *Clinical Therapeutics* 2011;**33**(3):358–71.
- Clarke 2004**  
Clarke R, Grimley Evans J, Schneede J, Nexo E, Bates C, Fletcher A, et al. Vitamin B12 and folate deficiency in later life. *Age and Ageing* 2004;**33**:34–41.
- De Jager 2010**  
De Jager J, Kooy A, Lehert P, Wulfelé MG, Van der Kolk J, Bets D, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. *BMJ* 2010;**340**:c2181.
- Elia 1998**  
Elia M. Oral or parenteral therapy for B12 deficiency. *Lancet* 1998;**352**(9142):1721–2.
- FAO/WHO 1988**  
Report of a Joint FAO/WHO Expert Consultation. Requirements of vitamin A, iron, folate and vitamin B12. Report of a Joint FAO/WHO Expert Consultation. *FAO Food and Nutrition Series*. Vol. 23, Rome: Food and Agriculture Organization of the United Nations; World Health Organization, 1988.
- Figlin 2003**  
Figlin E, Chetrit A, Shahar A, Shpilberg O, Zivelin A, Rosenberg N, et al. High prevalences of vitamin B12 and folic acid deficiency in elderly subjects in Israel. *British Journal of Haematology* 2003;**123**:696–701.
- Glass 1961**  
Glass GB, Skeggs HR, Lee DH, Jones EL, Hardy WW. Hydroxocobalamin. I. Blood levels and urinary excretion of vitamin B12 in man after a single parenteral dose of aqueous hydroxocobalamin, aqueous cyanocobalamin and cyanocobalamin zinc-tannate complex. *Blood* 1961;**18**:511–21.
- Graham 2007**  
Graham ID, Jette N, Tetroe J, Robinson N, Milne S, Mitchell SL. Oral cobalamin remains medicine's best kept

- secret. *Archives of Gerontology and Geriatrics* 2007;**44**(1): 49–59.
- Green 2013**  
Green. Physiology, dietary sources, and requirements. *Encyclopedia of Human Nutrition* 2013;**4**:351–6.
- Hall 1977**  
Hall CA. The carriers of native vitamin B12 in normal human serum. *Clinical Science and Molecular Medicine* 1977;**53**:453–7.
- Higgins 2002**  
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;**21**(11):1539–58.
- Higgins 2003**  
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. *BMJ* 2003;**327**: 557–60.
- Higgins 2009**  
Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 2009; **172**(1):137–59.
- Higgins 2011a**  
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
- Higgins 2011b**  
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;**343**: d5928.
- Hozo 2005**  
Hozo SR, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Medical Research Methodology* 2005;**5**:13. [DOI: 10.1186/1471-2288-5-13]
- Hróbjartsson 2013**  
Hróbjartsson A, Thomsen AS, Emanuelsson F, Tendal B, Hilden J, Boutron I, et al. Observer bias in randomized clinical trials with measurement scale outcomes: a systematic review of trials with both blinded and nonblinded assessors. *Canadian Medical Association Journal* 2013;**185** (4):E201–11.
- Kirkham 2010**  
Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. *BMJ* 2010;**340**:c365. [DOI: 10.1136/bmj.c365]
- Lam 2013**  
Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. *JAMA* 2013;**310**:2435–42.
- Lederle 1998**  
Lederle FA. Oral cobalamin for pernicious anemia: back from the verge of extinction. *Journal of the American Geriatrics Society* 1998;**46**:1125–7.
- Liberati 2009**  
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. *PLoS Medicine* 2009;**6**(7):1–28. [DOI: 10.1371/journal.pmed.1000100]
- Lindenbaum 1994**  
Lindenbaum J, Rosenberg IH, Wilson PW, Stabler SP, Allen RH. Prevalence of cobalamin deficiency in the Framingham elderly population. *American Journal of Clinical Nutrition* 1994;**60**(1):2–11.
- MacFarlane 2011**  
MacFarlane AJ, Greene-Finestone LS, Shi Y. Vitamin B-12 and homocysteine status in a folate-replete population. *American Journal of Clinical Nutrition* 2011;**94**(4):1079–87.
- Mathieu 2009**  
Mathieu S, Boutron I, Moher D, Altman DG, Ravaut P. Comparison of registered and published primary outcomes in randomized controlled trials. *JAMA* 2009;**302**:977–84.
- Meader 2014**  
Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. *Systematic Reviews* 2014;**3**:82.
- Middleton 1985**  
Middleton J, Wells W. Vitamin B12 injections: considerable source of work for the district nurse. *BMJ* 1985;**290**(6477): 1254–5.
- Nilsson 2005**  
Nilsson M, Norberg B, Hultdin J, Sandstrom H, Westman G, Lökk J. Medical intelligence in Sweden. Vitamin B12: oral compared with parenteral?. *Postgraduate Medical Journal* 2005;**81**:191–3.
- Pawlak 2013**  
Pawlak R, Parrott SJ, Raj S, Cullum-Dugan D, Lucus D. How prevalent is vitamin B12 deficiency among vegetarians? . *Nutrition Reviews* 2013;**71**(2):110–7.
- Pawlak 2015**  
Pawlak R. Is vitamin B12 deficiency a risk factor for cardiovascular disease in vegetarians?. *American Journal of Preventive Medicine* 2015;**48**(6):e11–26.
- Pennypacker 1992**  
Pennypacker LC, Allen RH, Kelly JP, Matthews LM, Grigsby J, Kaye K. High prevalence of cobalamin deficiency in elderly outpatients. *Journal of the American Geriatrics Society* 1992;**40**:1197–204.
- Quadros 2010**  
Quadros E. Advances in the understanding of cobalamin assimilation and metabolism. *British Journal of Haematology* 2010;**148**:195–204.
- Rajan 2002**  
Rajan S, Wallace JI, Beresford SA, Brodtkin KI, Allen RA, Stabler SP. Screening for cobalamin deficiency in geriatric outpatients: prevalence and influence of synthetic

- cobalamin intake. *Journal of the American Geriatrics Society* 2002;**50**(4):624–30.
- RevMan 2014 [Computer program]**  
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
- Rickes 1948**  
Rickes EL, Brink NG, Koniuszy FR, Wood TR, Folkers K. Crystalline vitamin B12. *Science* 1948;**107**:396.
- Riley 2011**  
Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ* 2011;**342**:d549.
- Schroll 2015**  
Schroll JB, Bero L. Regulatory agencies hold the key to improving Cochrane Reviews of drugs [editorial]. *Cochrane Database of Systematic Reviews* 2015; Vol. 4. [DOI: 10.1002/14651858.ED000098]
- Schünemann 2011**  
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from [handbook.cochrane.org](http://handbook.cochrane.org).
- Smith 1948**  
Smith EL. Purification of anti-pernicious anaemia factor from liver. *Nature* 1948;**161**:638.
- Stabler 2013**  
Stabler SP. Clinical practice. Vitamin B12 deficiency. *New England Journal of Medicine* 2013;**368**(2):149–60.
- Sterne 2011**  
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;**343**:d4002.
- van Walraven 1999**  
van Walraven C, Naylor CD. Use of vitamin B12 injections among elderly patients by primary care practitioners in Ontario. *Canadian Medical Association Journal* 1999;**161**: 146–9.
- Watanabe 2013**  
Watanabe F, Yabuta Y, Tanioka Y. Biologically active vitamin B12 compounds in foods for preventing deficiency among vegetarians and elderly. *Journal of Agricultural and Food Chemistry* 2013;**61**(28):6769–75.
- Wong 2006**  
Wong SSL, Wilczynski NL, Haynes RB. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. *Journal of the Medical Library Association* 2006;**94**(1):41–7.
- Wood 2008**  
Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ* 2008;**336** (7644):601–5.

## References to other published versions of this review

- Vidal-Alaball 2005**  
Vidal-Alaball J, Butler CC, Cannings-John R, Goringe A, Hood K, McCaddon A, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. *Cochrane Database of Systematic Reviews* 2005, Issue 3. [DOI: 10.1002/14651858.CD004655.pub2]

\* Indicates the major publication for the study

## CHARACTERISTICS OF STUDIES

### Characteristics of included studies [ordered by study ID]

#### Bolaman 2003

Methods	Parallel randomised controlled clinical trial; randomisation ratio 1:1; open label; observation period 90 days	
Participants	<p><b>Inclusion criteria:</b> people with megaloblastic anaemia due to vitamin B<sub>12</sub> deficiency</p> <ul style="list-style-type: none"> <li>• Age &gt; 15 years</li> <li>• Serum vitamin B<sub>12</sub> level &lt; 160 pg/mL</li> <li>• Megaloblastic anaemia</li> <li>• MCV &gt; 94 fL</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• vomiting or diarrhoea or both, alcohol use &gt; 40 g/d</li> <li>• unable to give informed consent</li> <li>• history of malignancy</li> <li>• folate deficiency</li> <li>• inability to ingest oral medication</li> <li>• use of medication that might interfere with folate metabolism</li> <li>• pregnant or possibly pregnant</li> <li>• breastfeeding</li> </ul> <p><b>Diagnostic criteria:</b> people with megaloblastic anaemia due to vitamin B<sub>12</sub> deficiency</p>	
Interventions	<p><b>Number of study centres:</b> 1</p> <p><b>Treatment before study:</b> unknown</p>	
Outcomes	<b>Composite outcome measures reported:</b> no	
Study details	<p><b>Run-in period:</b> none</p> <p><b>Study terminated early:</b> no</p>	
Publication details	<p><b>Language of publication:</b> English</p> <p><b>Commercial funding/non-commercial funding/other funding:</b> unknown</p> <p><b>Publication status:</b> peer-reviewed journal</p>	
Stated aim for study	<b>Quote from publication:</b> “This study assessed the effects and cost of PO versus IM vitamin B <sub>12</sub> treatment in patients with megaloblastic anaemia due to vitamin B <sub>12</sub> ”	
Notes		
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	<p><b>Quote from publication:</b> “using the block randomizations method”</p> <p><b>Comment:</b> no details provided</p>

**Bolaman 2003** (Continued)

Allocation concealment (selection bias)	Unclear risk	<b>Comment:</b> no details provided
Blinding of participants and personnel (performance bias) adverse events	High risk	<b>Quote from publication:</b> “open-label study” <b>Comment:</b> outcome measure likely to be influenced by lack of blinding
Blinding of participants and personnel (performance bias) haemoglobin and mean corpuscular volume (MCV)	Low risk	<b>Quote from publication:</b> “open-label” <b>Comment:</b> outcome measure unlikely to be influenced by lack of blinding
Blinding of participants and personnel (performance bias) serum vitamin B12 levels	Low risk	<b>Quote from publication:</b> “open-label” <b>Comment:</b> outcome measure unlikely to be influenced by lack of blinding
Blinding of participants and personnel (performance bias) socioeconomic effects	Low risk	<b>Quote from publication:</b> “open-label study” <b>Comment:</b> outcome measure unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) adverse events	High risk	<b>Quote from publication:</b> “open-label study” <b>Comment:</b> outcome measure likely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) haemoglobin and mean corpuscular volume (MCV)	Low risk	<b>Quote from publication:</b> “open-label study” <b>Comment:</b> outcome measure unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) serum vitamin B12 levels	Low risk	<b>Quote from publication:</b> “open-label study” <b>Comment:</b> outcome measure unlikely to be influenced by lack of blinding
Blinding of outcome assessment (detection bias) socioeconomic effects	Low risk	<b>Quote from publication:</b> “open-label study” <b>Comment:</b> outcome measure unlikely to be influenced by lack of blinding
Incomplete outcome data (attrition bias) adverse events	Low risk	<b>Quote from publication:</b> “No treatment-related adverse events were reported in either treatment group” <b>Comment:</b> no adverse events were reported



**Bolaman 2003** (Continued)

Incomplete outcome data (attrition bias) haemoglobin and mean corpuscular volume (MCV)	Unclear risk	<b>Comment:</b> 10 of 70 participants left the study because they did not appear for follow-up after 10 days of treatment
Incomplete outcome data (attrition bias) serum vitamin B12 levels	Unclear risk	<b>Comment:</b> 10 of 70 participants left the study because they did not appear for follow-up after 10 days of treatment
Incomplete outcome data (attrition bias) socioeconomic effects	Unclear risk	<b>Comment:</b> 10 of 70 participants left the study because they did not appear for follow-up after 10 days of treatment
Selective reporting (reporting bias)	Unclear risk	<b>Comment:</b> primary endpoint “improvements in signs and symptoms of anaemia” neither defined nor results reported, no protocol available
Other bias	Low risk	<b>Comment:</b> none detected

**Kuzminski 1998**

Methods	Parallel randomised controlled clinical trial; randomisation ratio 1:1; observation period 4 months
Participants	<p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Newly diagnosed vitamin B<sub>12</sub>-deficient participants</li> <li>• Serum vitamin B<sub>12</sub> level &lt; 160 pg/mL</li> <li>• Elevation of serum methylmalonic acid, total homocysteine or both metabolites &gt; 3 SDs above the mean in normal controls</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• Location outside immediate geographical area</li> <li>• Incapacity to give informed consent</li> <li>• Associated life-threatening illness</li> <li>• Primary folate deficiency</li> </ul> <p><b>Diagnostic criteria:</b> people with newly diagnosed vitamin B<sub>12</sub> deficiency (defined as serum vitamin B<sub>12</sub> concentrations less than 160 pg/mL)</p>
Interventions	<p><b>Number of study centres:</b> 4 centres</p> <p><b>Treatment before study:</b> unknown</p>
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<p><b>Run-in period:</b> none</p> <p><b>Study terminated early:</b> no</p>
Publication details	<p><b>Language of publication:</b> English</p> <p><b>Commercial funding/non-commercial funding/other funding:</b> unknown</p> <p><b>Publication status:</b> peer-reviewed journal</p>

**Kuzminski 1998** (Continued)

Stated aim for study	<b>Quote from publication:</b> “However, oral treatment with the vitamin has never been the subject of a controlled study. Therefore, we conducted a randomised, controlled trial of oral versus parenteral cyanocobalamin therapy in patients with vitamin B <sub>12</sub> deficiency”	
Notes		
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Low risk	<b>Quote from publication:</b> “... patients were randomized (Statistical Analysis System; SAS Institute, Cary, NC) ...” <b>Comment:</b> computer randomisation
Allocation concealment (selection bias)	Unclear risk	<b>Comment:</b> not reported
Blinding of participants and personnel (performance bias) haemoglobin and mean corpuscular volume (MCV)	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Blinding of participants and personnel (performance bias) serum vitamin B12 levels	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Blinding of participants and personnel (performance bias) total homocysteine and serum methylmalonic acid levels	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Blinding of outcome assessment (detection bias) haemoglobin and mean corpuscular volume (MCV)	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Blinding of outcome assessment (detection bias) serum vitamin B12 levels	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Blinding of outcome assessment (detection bias) total homocysteine and serum methylmalonic acid levels	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Incomplete outcome data (attrition bias) haemoglobin and mean corpuscular volume (MCV)	Low risk	<b>Comment:</b> outcomes measured for 33 participants (5 participants turned out to have low folate levels and were excluded post hoc). The missing data are not likely to im-

**Kuzminski 1998** (Continued)

		pact the effect
Incomplete outcome data (attrition bias) serum vitamin B12 levels	Low risk	<b>Comment:</b> outcomes measured for 33 participants (5 participants turned out to have low folate levels and were excluded post hoc). The missing data are not likely to impact the effect
Incomplete outcome data (attrition bias) total homocysteine and serum methylmalonic acid levels	Low risk	<b>Comment:</b> outcomes measured for 33 participants (5 participants turned out to have low folate levels and were excluded post hoc). The missing data are not likely to impact the effect
Selective reporting (reporting bias)	Unclear risk	<b>Comment:</b> no protocol available
Other bias	Low risk	<b>Comment:</b> none detected

**Saraswathy 2012**

Methods	Parallel randomised controlled clinical trial; randomisation ratio 1:1; non-inferiority design; observation period 3 months
Participants	<p><b>Inclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• diagnosed vitamin B<sub>12</sub>-deficient participants</li> <li>• Serum vitamin B<sub>12</sub> level &lt; 200 pg/mL</li> </ul> <p><b>Exclusion criteria:</b></p> <ul style="list-style-type: none"> <li>• people aged &lt; 18 years</li> <li>• pregnant individuals</li> <li>• those with special conditions mandating parenteral supplementation</li> <li>• those already on vitamin B<sub>12</sub> supplements</li> </ul> <p><b>Diagnostic criteria:</b> people with newly diagnosed vitamin B<sub>12</sub> deficiency (defined as serum vitamin B<sub>12</sub> concentrations less than 200 pg/mL)</p>
Interventions	<p><b>Number of study centres:</b> 1</p> <p><b>Treatment before study:</b> unknown</p> <p><b>Titration period:</b> not applicable</p>
Outcomes	<b>Composite outcome measures reported:</b> no
Study details	<p><b>Run-in period:</b> none</p> <p><b>Study terminated before regular end:</b> no</p>
Publication details	<p><b>Language of publication:</b> English</p> <p><b>Commercial funding/non-commercial funding/other funding:</b> unknown</p> <p><b>Publication status:</b> peer-reviewed journal; conference abstract providing sufficient information</p>

Stated aim for study	<b>Quote from publication:</b> “To compare the efficacy of oral versus intramuscular vitamin B <sub>12</sub> supplementation for the treatment of vitamin B <sub>12</sub> deficiency”	
Notes		
<b>Risk of bias</b>		
<b>Bias</b>	<b>Authors’ judgement</b>	<b>Support for judgement</b>
Random sequence generation (selection bias)	Unclear risk	<b>Quote from publication:</b> “... randomised and allocated in a concealed manner ...” <b>Comment:</b> the method of randomisation is not reported
Allocation concealment (selection bias)	Unclear risk	<b>Quote from publication:</b> “... randomised and allocated in a concealed manner ...” <b>Comment:</b> the allocation was concealed, but no details were provided.
Blinding of participants and personnel (performance bias) adverse events	High risk	<b>Quote from publication:</b> “Randomized open label trial ...” <b>Comment:</b> not reported, outcome measure likely to be influenced by lack of blinding
Blinding of participants and personnel (performance bias) serum vitamin B12 levels	Low risk	<b>Quote from publication:</b> “Randomized open label trial ...” <b>Comment:</b> not reported, outcome measure unlikely to be affected by lack of blinding
Blinding of participants and personnel (performance bias) socioeconomic effects	Low risk	<b>Quote from publication:</b> “Randomized open label trial ...” <b>Comment:</b> not reported, outcome measure unlikely to be affected by lack of blinding
Blinding of outcome assessment (detection bias) serum vitamin B12 levels	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Blinding of outcome assessment (detection bias) socioeconomic effects	Low risk	<b>Comment:</b> not reported, outcome measure unlikely to be affected by blinding conditions
Incomplete outcome data (attrition bias) serum vitamin B12 levels	High risk	<b>Comment:</b> 8 participants in the intervention group (oral vitamin B <sub>12</sub> ) left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2). 3 participants in the control group (intramuscular vitamin B <sub>12</sub> )

		left the trial early due to expired (n = 1) and loss to follow-up (n = 2). The attrition rate is high (18.3%), and the missing data are likely to have an impact on the estimate of effect
Incomplete outcome data (attrition bias) socioeconomic effects	High risk	<b>Comment:</b> 8 participants in the intervention group (oral vitamin B <sub>12</sub> ) left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2). 3 participants in the control group (intramuscular vitamin B <sub>12</sub> ) left the trial early due to expired (n = 1) and loss to follow-up (n = 2). The attrition rate is high (18.3%), and the missing data are likely to have an impact on the estimate of effect
Selective reporting (reporting bias)	Unclear risk	<b>Comment:</b> no protocol
Other bias	Low risk	<b>Comment:</b> none detected

Note: blank cells indicate that the particular outcome was not measured in trial.  
IM: intramuscular; MCV: mean corpuscular volume; PO: peroral; SD: standard deviation

### Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
<a href="#">Aguilar 2004</a>	Commentary
<a href="#">Andres 2005a</a>	Review
<a href="#">Andres 2005b</a>	Letter
<a href="#">Andres 2011</a>	Letter
<a href="#">Andres 2012</a>	Review
<a href="#">Bharath 2015</a>	Case report
<a href="#">Bharatwaj 2012</a>	Review
<a href="#">Butler 2006</a>	Systematic review

(Continued)

Castelli 2010	Participants without vitamin B <sub>12</sub> deficiency but low vitamin B <sub>12</sub> levels only (overall mean: 273 pg/mL (SD 55.2), i.e. borderline result)
Emans 2013	Letter
EUCTR 2013-004835-60	Non-randomised trial
Geisel 2005	Non-randomised trial
Haffner 2016	Review of the evidence
Houle 2014	Cost analysis
ISRCTN22063938	Oral vitamin B <sub>12</sub> versus placebo
Kim 2011	Non-randomised single-arm trial
Kolber 2014	Non-randomised trial
Kripke 2006	Non-randomised trial
Leidenmuhler 2013	All participants received a multivitamin mineral supplementation on a daily basis
Leon 2013	Commentary
Lin 2012	Commentary
Lonn 2006	Letter
Masucci 2013	Review
Metaxas 2013	Review
Metaxas 2017	Eligible participants had a vitamin B <sub>12</sub> level < 200 pmol/L (i.e. borderline result), mean vitamin B <sub>12</sub> levels at inclusion were 158 pmol/L ± 27 pmol/L and 164 pmol/L ± 20 pmol/L for the oral and intramuscular group, respectively
NCT00699478	Non-randomised single-arm trial
Pacholok 2013	Commentary
Radziwill 2014	Commentary
Schijns 2016	Mean vitamin B <sub>12</sub> levels at inclusion were 170 pmol/L ± 22 pmol/L (i.e. borderline result), also conference abstract only
Schloss 2015	Case report

(Continued)

Stabler 2015	Review
--------------	--------

SD: standard deviation

### Characteristics of studies awaiting assessment [ordered by study ID]

#### Ashok 2011

Methods	Randomised, parallel-group trial; total sample size N = 38
Participants	<b>Diagnosis:</b> all participants with documented vitamin B <sub>12</sub> deficiency (serum vitamin B <sub>12</sub> level < 200 pg/mL) <b>Age:</b> 18 to 80 years old <b>Exclusion criteria:</b> <ul style="list-style-type: none"><li>• age less than 18 years</li><li>• pregnant individuals</li><li>• renal failure</li><li>• special cases where parenteral B<sub>12</sub> supplementation is mandatory (e.g. people with severe neurological deficits, intestinal failure, etc.)</li><li>• already taking vitamin B<sub>12</sub> supplements</li></ul>
Interventions	<b>Group 1:</b> oral vitamin B <sub>12</sub> 1000 mcg once daily for 3 months <b>Group 2:</b> intramuscular injections of vitamin B <sub>12</sub> once daily for a week, followed by once a week for 8 weeks, followed by once-a-month injection for 1 month (total duration 3 months)
Outcomes	<b>Primary outcome:</b> serum vitamin B <sub>12</sub> levels (3 months after initiation of therapy) <b>Secondary outcomes:</b> change in haemoglobin, mean corpuscular volume, serum homocysteine, clinical symptoms (3 months)
Notes	Awaiting full text <b>Contact information:</b> Arun RS, assistant professor, Christian Medical College, Vellore; drarunrs@gmail.com Ashok Chacko, professor and head, Christian Medical College, Vellore; chacko.ashok@gmail.com Trial was registered retrospectively; trial is completed.

### Characteristics of ongoing studies [ordered by study ID]

#### EUCTR 2009-014468-20-AT

Trial name or title	<b>Acronym:</b> not stated
Methods	<b>Type of study:</b> not stated <b>Allocation:</b> not stated <b>Intervention model:</b> not stated <b>Masking:</b> not stated

**EUCTR 2009-014468-20-AT** (Continued)

	<b>Primary purpose:</b> not stated
Participants	<b>Condition:</b> vitamin B <sub>12</sub> deficiency undergoing gastric bypass surgery <b>Enrolment:</b> not stated <b>Inclusion criteria:</b> not stated <b>Exclusion criteria:</b> not stated
Interventions	<b>Intervention(s):</b> sublingual vitamin B <sub>12</sub> <b>Comparator(s):</b> intramuscular vitamin B <sub>12</sub>
Outcomes	<b>Primary outcome(s):</b> not stated <b>Secondary outcome(s):</b> not stated <b>Other outcome(s):</b> not stated
Starting date	<b>Study start date:</b> 22 March 2010 <b>Study completion date:</b> not stated
Contact information	<b>Responsible party/principal investigator:</b> Medizinische Universität Wien, Univ.Klinik für Chirurgie, Abt.für Allgemein Chirurgie
Study identifier	<b>EudraCT number:</b> EUCTR2009-014468-20-AT
Official title	A prospective comparison of vitamin B <sub>12</sub> supplementation after gastric bypass surgery (sublingual vs intramuscular)
Stated purpose of study	Not stated
Notes	

**NCT01476007**

Trial name or title	<b>Acronym:</b> Project OB12
Methods	<b>Type of study:</b> non-inferiority clinical trial <b>Allocation:</b> randomisation <b>Intervention model:</b> parallel assignment <b>Masking:</b> open label <b>Primary purpose:</b> treatment
Participants	<b>Condition:</b> vitamin B <sub>12</sub> deficiency, defined as serum vitamin B <sub>12</sub> < 179 pg/mL <b>Enrolment:</b> estimated 320 <b>Inclusion criteria:</b> <ul style="list-style-type: none"> <li>• ≥ 65 aged patients with vitamin B<sub>12</sub> deficiency</li> <li>• participants give informed consent</li> </ul> <b>Exclusion criteria:</b> <ul style="list-style-type: none"> <li>• treatment with B<sub>12</sub> (last year)</li> <li>• neurologic or psychiatric pathologies</li> <li>• folic acid &lt; 2.3 ng/mL</li> </ul>



Interventions	<b>Intervention(s):</b> oral vitamin B <sub>12</sub> <b>Comparator(s):</b> intramuscular vitamin B <sub>12</sub>
Outcomes	<b>Primary outcome(s):</b> <ul style="list-style-type: none"> <li>• change from baseline in vitamin B<sub>12</sub> level at 52 weeks</li> <li>• change from vitamin B<sub>12</sub> level standardisation</li> </ul> <b>Secondary outcome(s):</b> not stated <b>Other outcome(s):</b> none
Starting date	<b>Study start date:</b> July 2014; ongoing but not recruiting participants <b>Study completion date:</b> December 2017
Contact information	<b>Responsible party/principal investigator:</b> Esperanza Escortell, Epidemiology, phone 34 91 3352569, email eescortell@salud.madrid.org Rosario Riesgo, Epidemiology, phone 34 91 6956672, email rriesgo@salud.madrid.org
Study identifier	ClinicalTrials.gov: NCT01476007 EudraCT number: 2010-024129-20
Official title	Oral/intramuscular B <sub>12</sub> to treat cobalamin deficiency
Stated purpose of study	To determine the effectiveness of oral versus intramuscular vitamin B <sub>12</sub> by restore vitamin B <sub>12</sub> parameter in blood at 8, 26, and 52 weeks in ≥ 65 aged patients with vitamin B <sub>12</sub> deficiency
Notes	<b>NCT number:</b> NCT01476007

## DATA AND ANALYSES

### Comparison 1. Oral versus intramuscular vitamin B<sub>12</sub>


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Serum vitamin B <sub>12</sub> levels	2		Mean Difference (IV, Random, 95% CI)	Totals not selected
2 Number of participants with normalisation of serum vitamin B <sub>12</sub> deficiency	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
3 Adverse events	1		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
4 Haemoglobin	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
5 Mean corpuscular volume	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
6 Total homocysteine	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
7 Serum methylmalonic acid	1		Mean Difference (IV, Random, 95% CI)	Subtotals only

#### Analysis 1.1. Comparison 1 Oral versus intramuscular vitamin B<sub>12</sub>, Outcome 1 Serum vitamin B<sub>12</sub> levels.

Review: Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency

Comparison: 1 Oral versus intramuscular vitamin B<sub>12</sub>

Outcome: 1 Serum vitamin B<sub>12</sub> levels




**Analysis 1.2. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 2 Number of participants with normalisation of serum vitamin B12 deficiency.**

Review: Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency

Comparison: 1 Oral versus intramuscular vitamin B<sub>12</sub>

Outcome: 2 Number of participants with normalisation of serum vitamin B<sub>12</sub> deficiency




**Analysis 1.3. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 3 Adverse events.**

Review: Oral vitamin B<sub>12</sub> versus intramuscular vitamin B<sub>12</sub> for vitamin B<sub>12</sub> deficiency

Comparison: 1 Oral versus intramuscular vitamin B<sub>12</sub>

Outcome: 3 Adverse events



### Analysis 1.4. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 4 Haemoglobin.

Review: Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

Comparison: 1 Oral versus intramuscular vitamin B12

Outcome: 4 Haemoglobin




### Analysis 1.5. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 5 Mean corpuscular volume.

Review: Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

Comparison: 1 Oral versus intramuscular vitamin B12

Outcome: 5 Mean corpuscular volume




### Analysis 1.6. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 6 Total homocysteine.

Review: Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

Comparison: 1 Oral versus intramuscular vitamin B12

Outcome: 6 Total homocysteine




### Analysis 1.7. Comparison 1 Oral versus intramuscular vitamin B12, Outcome 7 Serum methylmalonic acid.

Review: Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency

Comparison: 1 Oral versus intramuscular vitamin B12

Outcome: 7 Serum methylmalonic acid



## ADDITIONAL TABLES

Table 1. Overview of trial populations

	Intervention(s) and comparator (s)	Description of power and sample size calculation	Screened/eligible (N)	Randomised (N)	Analysed (N)	Finishing trial (N)	Randomised finishing trial (%)	Follow-up (extended follow-up) <sup>a</sup>
<b>Bolaman 2003 (parallel RCT)</b>	I: 1000 µg oral vitamin B <sub>12</sub>	-	-	26	26	26	100	90 days (none)
	C: 1000 µg IM vitamin B <sub>12</sub>			34	34	34	100	
	<b>Total:</b>			<b>60<sup>b</sup></b>	<b>60</b>	<b>60</b>	<b>100</b>	
<b>Kuzminski 1998 (parallel RCT)</b>	I: 2000 µg oral vitamin B <sub>12</sub>	-	138	18	18	18	100	4 months (none)
	C: 1000 µg IM vitamin B <sub>12</sub>			15	15	15	100	
	<b>Total:</b>			<b>33<sup>c</sup></b>	<b>33</b>	<b>33</b>	<b>100</b>	
<b>Saraswathy 2012 (parallel RCT)</b>	I: 1000 µg oral vitamin B <sub>12</sub>	"Sample size was estimated to be 23 in each study arm, assuming equal response of 90% and non inferiority margin of 25% /alpha = 0.	-	30	22	22	73	3 months (none)
	C: 1000 µg IM vitamin B <sub>12</sub>			30	27	27	90	
	<b>Total:</b>			<b>60</b>	<b>49</b>	<b>49</b>	<b>82</b>	
<b>Grand total</b>	<i>All interventions</i>			<b>74</b>		<b>66</b>		
	<i>All comparators</i>			<b>79</b>		<b>76</b>		

**Table 1. Overview of trial populations** (Continued)

<i>All interventions and comparators</i>	153	142
--	-----	-----

- denotes not reported

C: comparator; I: intervention; IM: intramuscular; RCT: randomised controlled trial

<sup>a</sup>Follow-up under randomised conditions until end of trial (= duration of intervention + follow-up postintervention or identical to duration of intervention); extended follow-up refers to follow-up of participants once the original trial was terminated as specified in the power calculation.

<sup>b</sup>Of 70 participants enrolled in the trial, 10 were excluded because of failure to appear for follow-up after 10 days of treatment.

<sup>c</sup>38 participants were randomised; after completion of the trial 5 participants were judged to have primary folate deficiency rather than vitamin B<sub>12</sub> deficiency and were excluded from the final analysis.

## APPENDICES

### Appendix I. Search strategies

#### Cochrane Library

1. [mh "Vitamin B 12"]
2. ((vitamin\* or vit or coenzym\*) near/1 (b12 or "b 12" or b12? or "b 12?")):ti,ab
3. (cobalamin\* or hydrox?cobalamin\* or c?anocobalamin\* or methylcobalamin\* or adenosylcobalamin\* or dibenzocid\* or cobamamid\* or cobamid\*):ti,ab
4. {or #1-#3}
5. [mh "Vitamin B 12 Deficiency"]
6. ((b12 or "b 12" or b12? or "b 12?" or cobalamin\* or cyanocobalamin) near/3 deficien\*):ti,ab
7. #5 or #6
8. #4 and #7 [Publication Year from 2005 to 2017]

#### MEDLINE (Ovid SP)

1. exp Vitamin B 12/
2. ((vitamin\* or vit or coenzym\*) adj1 (b12? or "b 12?")):tw
3. (cobalamin\* or hydrox?cobalamin\* or c?anocobalamin\* or methylcobalamin\* or adenosylcobalamin\* or dibenzocid\* or cobamamid\* or cobamid\*):tw
4. or/1-3
5. exp Vitamin B 12 Deficiency/
6. ((b12? or "b 12?" or cobalamin\* or cyanocobalamin) adj3 deficien\*):tw
7. or/5-6
8. 4 and 7

(Continued)

[9-19: *Cochrane Handbook 2008 RCT filter - sensitivity max. version*]

9. randomized controlled trial.pt.
10. controlled clinical trial.pt.
11. randomi?ed.ab.
12. placebo.ab.
13. drug therapy.fs.
14. randomly.ab.
15. trial.ab.
16. groups.ab.
17. or/9-16
18. exp animals/ not humans/
19. 17 not 18
20. 8 and 19
21. (200412?? or 2005\* or 2006\* or 2007\* or 2008\* or 2009 or 201\*).dc
22. 20 and 21

---

#### Embase (Ovid SP)

1. cobalamin derivative/
  2. hydroxocobalamin/
  3. methylcobalamin/
  4. cyanocobalamin/
  5. cobamamide/
  6. cobalamin/
  7. ((vitamin\* or vit or coenzym\*) adj1 (b12? or "b 12?")).tw
  8. (cobalamin\* or hydrox?cobalamin\* or c?anocobalamin\* or methylcobalamin\* or adenosylcobalamin\* or dibencozid\* or cobamamid\* or cobamid\*).tw
  9. or/1-8
  10. cyanocobalamin deficiency/
  11. ((b12? or "b 12?" or cobalamin\* or cyanocobalamin) adj3 deficien\*).tw
  12. or/10-11
  13. 9 and 12
- [13 [Wong 2006](#) "sound treatment studies" filter - BS version]
14. random\*.tw. or clinical trial\*.mp. or exp health care quality/
  15. 13 and 14
  16. (200412?? or 2005\* or 2006\* or 2007\* or 2008\* or 2009 or 201\*).dc
  17. 15 and 16

---

#### LILACS (iAHx)

(MH: "Vitamin B 12" OR ((vitamin\$ OR coenzym\$ OR coenzim\$) AND (B12 OR "B 12"))) OR (cobalamin\$ OR hydroxocobalamin\$ OR hydroxocobalamin\$ hidroxicobalamin\$ OR hidroxicobalamin\$ OR cyanocobalamin\$ OR cianocobalamin\$ OR methylcobalamin\$ OR metilcobalamin\$ OR adenosylcobalamin\$ OR adenosilcobalamin\$ OR dibencozid\$ OR cobamamid\$ OR cobamid\$) AND (MH: "Vitamin B 12 Deficiency" OR ((B12 OR "B 12" OR cobalamin\$ OR cyanocobalamin\$ OR cianocobalamin\$) AND deficien\$))  
+ Filter "Controlled Clinical Trial"

---

#### ClinicalTrials.gov (Expert search)



(Continued)

( hydroxocobalamin OR hydroxicobalamin OR methylcobalamin OR cyanocobalamin OR cobamamide OR cobalamin OR dibenzozid OR adenosylcobalamin OR cobamide OR “vitamin B12” OR “vitamin B 12” OR “coenzym B12” OR “coenzym B 12” ) AND ( B12 OR “B 12” OR cobalamin OR cyanocobalamin ) AND ( deficiency OR deficiencies OR deficient ) AND EXACT “Interventional” [STUDY-TYPES]

**ICTRP Search Portal (Standard search)**

deficien\* AND vitamin B12 OR  
 deficien\* AND vitamin B 12 OR  
 vitamin B12 deficiency OR  
 vitamin B 12 deficiency OR  
 deficien\* AND cobalamin\* OR  
 deficien\* AND cyanocobalamin\*

**Appendix 2. Description of interventions**

<b>Trial ID</b>	<b>Intervention(s) (route, frequency, total dose/day)</b>	<b>Comparator(s) (route, frequency, total dose/day)</b>
<b>Bolaman 2003</b>	Oral: 1000 µg cyanocobalamin (ampoule mixed with 20 mL fruit juice) self administered once daily for 10 days; after 10 days, once a week for 4 weeks and then once a month for life	Intramuscular: 1000 µg cyanocobalamin (ampoule, injection by a nurse into the gluteus muscle) once daily for 10 days; after 10 days, once a week for 4 weeks and then once a month for life
<b>Kuzminski 1998</b>	Oral: 2000 µg cyanocobalamin (two 1000 µg tablets) with breakfast daily for 4 months	Intramuscular: 1000 µg cyanocobalamin on days 1, 3, 7, 10, 14, 21, 30, 60, and 90 (injection by a nurse)
<b>Saraswathy 2012</b>	Oral: 1000 µg of vitamin B <sub>12</sub> daily for 3 months	Intramuscular: 1000 µg of vitamin B <sub>12</sub> once daily for a week followed by once a week for 8 weeks

**Appendix 3. Baseline characteristics (I)**

<b>Trial ID</b>	<b>Intervention(s) and comparator(s)</b>	<b>Duration of intervention (duration of follow-up)</b>	<b>Description of participants</b>	<b>Trial period (year to year)</b>	<b>Country</b>	<b>Setting</b>	<b>Ethnic groups (%)</b>	<b>Duration of vitamin B<sub>12</sub> deficiency (mean years (SD))</b>	<b>Vitamin B<sub>12</sub> levels (mean pg/mL (SD))</b>
-----------------	--	---	------------------------------------	------------------------------------	----------------	----------------	--------------------------	--	--

(Continued)

<b>Bolaman 2003</b>	I: oral vitamin B <sub>12</sub>	90 days (90 days)	People with megaloblastic anaemia due to vitamin B <sub>12</sub> deficiency (defined as serum vitamin B <sub>12</sub> level < 160 pg/mL)	1999 to 2003	Turkey	Hospital	-	-	72.9 (54.8)
	C: intramuscular vitamin B <sub>12</sub>	90 days (90 days)							70.2 (59.1)
<b>Kuzminski 1998</b>	I: oral vitamin B <sub>12</sub>	4 months (4 months)	People with newly diagnosed vitamin B <sub>12</sub> deficiency (defined as serum vitamin B <sub>12</sub> level < 160 pg/mL)	1993 to 1996	USA	Ambulatory care centres	White: 97 Latina: 3	-	93 (46)
	C: intramuscular vitamin B <sub>12</sub>	90 days (4 months)							95 (92)
<b>Saraswathy 2012</b>	I: oral vitamin B <sub>12</sub>	3 months (3 months)	Consecutive patients with vitamin B <sub>12</sub> deficiency (serum vitamin B <sub>12</sub> level < 200 pg/mL)	2009 to 2010	South India	A tertiary care hospital	-	-	149.8 (37.6)
	C: intramuscular vitamin B <sub>12</sub>	9 weeks (3 months)							146.0 (42.1)

- denotes not reported

C: comparator; I: intervention; SD: standard deviation

## Appendix 4. Baseline characteristics (II)

Trial ID	Intervention(s) and comparator(s)	Sex (female %)	Age (mean years (SD))	MCV (mean fL (SD))	Haemoglobin (mean g/dL (SD))	Total homocysteine (mean $\mu\text{mol/L}$ (SD))	Serum methylmalonic acid (mean $\text{nmol/L}$ (SD))	Comedications/Counterinterventions	Comorbidities
<b>Bolaman 2003</b>	I: oral vitamin B <sub>12</sub>	39	60 (15)	112.3 (11.4)	8.4 (2.1)	-	-	18/26 participants with upper GI endoscopy	Atrophic gastritis: 5 Chronic antral gastritis: 5 Chronic pangastritis: 3 Enterogastric reflux: 2 Alkaline reflux: 2
	C: intramuscular vitamin B <sub>12</sub>	50	64 (10)	114.8 (10.9)	8.3 (2.3)	-	-	27/34 participants with upper GI endoscopy	Atrophic gastritis: 9 Chronic antral gastritis: 2 Chronic pangastritis: 4 Enterogastric reflux: 2 Alkaline reflux: 4 Erosive gastritis: 1
<b>Kuzminski 1998</b>	I: oral vitamin B <sub>12</sub>	67	72 (11)	100 (12)	-	37.2 (44.9)	3850 (6930)	-	Atrophic gastritis: 7 (3 unclear) Pernicious anaemia: 5 Inadequate dietary pro-

(Continued)

										tein intake: 3
	C: intra- muscu- lar vitamin B <sub>12</sub>	87	71 (15)	102 (11)	-	40.0 (26.2)	3630 (7040)	-	-	Atrophic gastritis: 7 Pernicious anaemia: 2 Inad- equately dietary pro- tein intake: 2 Prior ileal resec- tion: 1 Prior gastric stap- ling: 1
<b>Saraswathy 2012</b>	I: oral vita- min B <sub>12</sub>	36.7	38.6 (14.8)	92.8 (14.3)	11.7 (2.4)	-	-	-	-	-
	C: intra- muscu- lar vitamin B <sub>12</sub>	16.7	44.3 (9.3)	89.4 (16.3)	12.4 (2.7)	-	-	-	-	-
<p>- denotes not reported C: comparator; GI: gastrointestinal tract; I: intervention; MCV: mean corpuscular volume; SD: standard deviation</p>										

## Appendix 5. Matrix of trial endpoints (publications and trial documents)

Trial ID	Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufacturer's website, published design paper) <sup>a</sup>	Trial results/publications available in trial register	Endpoints quoted in publication(s) <sup>b,c</sup>	Endpoints quoted in abstract of publication(s) <sup>b,c</sup>
<b>Saraswathy 2012</b>	Source: N/T		No full publication	<b>Primary outcome measure:</b> proportion of participants with serum vitamin B <sub>12</sub> normalisation ( $\geq 200$ pg/mL) after 60 days of

(Continued)

			treatment
			<b>Secondary outcome measure:</b> compliance: ensured by pill/ampoule count and verification of injection records
			<b>Other outcome measure(s):</b> -
<b>Bolaman 2003</b>	<b>Source:</b> N/T	<b>Primary outcome measure(s):</b> -	<b>Primary outcome measure(s):</b> -
		<b>Secondary outcome measure(s):</b> -	<b>Secondary outcome measure(s):</b> -
		<b>Other outcome measure(s)</b> : haemoglobin level, improvements in signs and symptoms of anaemia; response to therapy (detection of reticulocytosis between days 5 and 10, and recovery of the haematologic parameters on complete blood counts and peripheral blood smears at days 10, 30, and 90 of treatment); tolerability - adverse events (assessed by a haematologist at days 0, 30, and 90 using laboratory tests, e.g. serum potassium level, eosinophilia on blood smear, and patient interviews); costs (costs of the study drug and of the injections); serum vitamin B <sub>12</sub> levels; serum autoantibodies to gastric parietal cells; cognitive function (Mini-Mental State Examination); vibration threshold; neuro-	<b>Other outcome measure(s):</b> therapeutic effectiveness (haematologic parameters on days 0, 10, 30, and 90); serum vitamin B <sub>12</sub> (on days 0 and 90); cognitive function, vibration threshold; neurologic sensory assessment; tolerability

(Continued)

			logic sensory assessment (soft-touch, pinprick examination)	
Kuzminski 1998	Source: N/T		<b>Primary outcome measure(s): -</b>	<b>Primary outcome measure(s): -</b>
			<b>Secondary outcome measure(s): -</b>	<b>Secondary outcome measure(s): -</b>
			<b>Other outcome measure(s):</b> serum vitamin B <sub>12</sub> levels, serum folate levels, serum anti-intrinsic factor antibodies, unsaturated serum cobalamin-binding capacity, serum methylmalonic acid levels, serum homocysteine levels, serum pepsinogen I levels, neurologic symptoms, haematocrit, mean corpuscular volume	<b>Other outcome measure(s):</b> therapeutic effectiveness: haematologic and neurologic improvement and changes in serum levels of cobalamin (normal: 200 to 900 pg/mL), methylmalonic acid (normal: 73 to 271 nmol/L), and homocysteine (normal: 5.1 to 13.9 µmol/L)

- denotes not reported

EMA: European Medicines Agency; FDA: US Food and Drug Administration; N/T: no trial document available

<sup>a</sup>Trial document(s) refers to all available information from published design papers and sources other than regular publications (e.g. FDA/EMA documents, manufacturer's websites, trial registers).

<sup>b</sup>Publication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion documents or multiple reports of a primary trial).

<sup>c</sup>Other outcome measures refers to all outcomes not specified as primary or secondary outcome measures

## Appendix 6. High risk of outcome reporting bias according to Outcome Reporting Bias In Trials (ORBIT) classification

Trial ID	Outcome	High risk of bias (category A) <sup>a</sup>	High risk of bias (category D) <sup>b</sup>	High risk of bias (category E) <sup>c</sup>	High risk of bias (category G) <sup>d</sup>
Bolaman 2003	Clinical signs and symptoms of vitamin B <sub>12</sub> deficiency	No	Yes	No	No
Kuzminski 1998	N/A				
Saraswathy 2012	N/A				

(Continued)

N/A: not applicable

<sup>a</sup>Clear that outcome was measured and analysed; trial report states that outcome was analysed but only reports that result was not significant.

(Classification 'A', table 2, [Kirkham 2010](#))

<sup>b</sup>Clear that outcome was measured and analysed; trial report states that outcome was analysed but no results reported.

(Classification 'D', table 2, [Kirkham 2010](#))

<sup>c</sup>Clear that outcome was measured; clear that outcome was measured but not necessarily analysed; judgement says likely to have been analysed but not reported due to non-significant results.

(Classification 'E', table 2, [Kirkham 2010](#))

<sup>d</sup>Unclear whether the outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but not reported on the basis of non-significant results.

(Classification 'G', table 2, [Kirkham 2010](#))

## Appendix 7. Definition of endpoint measurement<sup>a</sup>

Trial ID	Definition of vitamin B <sub>12</sub> deficiency	Therapeutic efficacy	Clinical signs and symptoms of vitamin B <sub>12</sub> deficiency	Adverse events	Health-related quality of life	Acceptability	Socioeconomic effects
<b>Bolaman 2003</b>	Serum vitamin B <sub>12</sub> concentrations < 160 pg/mL, megaloblastic anaemia, mean corpuscular volume > 94 fL (IO)	Response to therapy (detection of reticulocytosis between days 5 and 10, and recovery of the haematologic parameters on complete blood counts and peripheral blood smears at days 10, 30, and 90 of treatment) (IO)	Cognitive function (Mini-Mental State Examination)	Tolerability - adverse events (assessed by a haematologist at days 0, 30, and 90 using laboratory tests, e.g. serum potassium level, eosinophilia on blood smear, and participant interviews) (IO)	N/I	Tolerability - adverse events (assessed by a haematologist at days 0, 30, and 90 using laboratory tests, e.g. serum potassium level, eosinophilia on blood smear, and participant interviews) (IO)	Costs of the study drug and of the injections (IO)
<b>Kuzminski 1998</b>	Serum vitamin B <sub>12</sub> concentrations < 160 pg/mL (IO)	Haematologic and neurologic improvement and changes in serum levels of	"Neurologic improvement" (IO)	N/I	N/I	N/I	N/I

(Continued)

		vitamin B <sub>12</sub> (normal: 200 to 900 pg/mL), methylmalonic acid (normal: 73 to 271 nmol/L), and homocysteine (normal: 5.1 to 13.9 µmol/L) (IO)						
<b>Saraswathy 2012</b>	Serum vitamin B <sub>12</sub> concentrations < 200 pg/mL (IO)	Proportion of participants in each treatment arm in whom vitamin B <sub>12</sub> levels were normalised (≥ 200 ng/mL) at 3 months after initial treatment	N/I	N/I	N/I	N/I	N/I	N/I

AO: adjudicated outcome measurement; IO: investigator-assessed outcome measurement; N/I: not investigated; SO: self reported outcome measurement

<sup>a</sup>In addition to definition of endpoint measurement, description of who measured the outcome (AO: adjudicated outcome measurement; IO: investigator-assessed outcome measurement; SO: self reported outcome measurement)

## Appendix 8. Adverse events (I)

Trial ID	Intervention(s) and comparator (s)	Participants included in analysis (N)	Deaths (N)	Deaths (%)	Participants with adverse events (N)	Participants with adverse events (%)	Participants with severe/serious adverse events (N)	Participants with severe/serious adverse events (%)
<b>Bolaman 2003</b>	I: oral vitamin B <sub>12</sub>	26 <sup>a</sup>	0	0	0	0	0	0
	C: intramuscular vitamin B <sub>12</sub>	34 <sup>a</sup>	0	0	0	0	0	0



(Continued)

<b>Kuzminski 1998</b>	I: oral vitamin B <sub>12</sub>	18 <sup>b</sup>	0	0	-	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	15 <sup>b</sup>	0	0	-	-	-	-
<b>Saraswathy 2012</b>	I: oral vitamin B <sub>12</sub>	22 <sup>c</sup>	0	0	-	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	27 <sup>d</sup>	0	0	-	-	-	-

- denotes not reported

C: comparator; I: intervention

<sup>a</sup>Ten participants in [Bolaman 2003](#) left the trial early, and the group assignment of the 10 participants was not reported (“no treatment related adverse events were reported in either treatment group”)

<sup>b</sup>Five participants in [Kuzminski 1998](#) were judged to have deficiency of primary folate rather than of cobalamin, therefore they were excluded from the data analysis

<sup>c</sup>Eight participants in this group left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2)

<sup>d</sup>Three participants in this group left the trial early due to expired (n = 1) and loss to follow-up (n = 2)

## Appendix 9. Adverse events (II)

Trial ID	Intervention(s) and comparator (s)	Participants included in analysis (N)	Participants discontinuing study due to adverse events (N)	Participants discontinuing study due to adverse events (%)	Participants hospitalised (N)	Participants hospitalised (%)	Participants with outpatient treatment (N)	Participants with outpatient treatment (%)
<b>Bolaman 2003</b>	I: oral vitamin B <sub>12</sub>	26 <sup>a</sup>	0	0	-	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	34 <sup>a</sup>	0	0	-	-	-	-
<b>Kuzminski 1998</b>	I: oral vitamin B <sub>12</sub>	18 <sup>b</sup>	-	-	-	-	-	-

(Continued)

	C: intramuscular vitamin B <sub>12</sub>	15 <sup>b</sup>	-	-	-	-	-	-
<b>Saraswathy 2012</b>	I: oral vitamin B <sub>12</sub>	22 <sup>c</sup>	2	6.7	-	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	27 <sup>d</sup>	0	0	-	-	-	-

- denotes not reported

C: comparator; I: intervention

<sup>a</sup>Ten participants in [Bolaman 2003](#) left the trial early, and the group assignment of the 10 participants was not reported

<sup>b</sup>Five participants in [Kuzminski 1998](#) were judged to have deficiency of primary folate rather than of cobalamin, therefore they were excluded from the data analysis

<sup>c</sup>Eight participants in this group left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2)

<sup>d</sup>Three participants in this group left the trial early due to expired (n = 1) and loss to follow-up (n = 2)

### Appendix 10. Adverse events (III)

Trial ID	Intervention(s) and comparator(s)	Participants included in analysis (N)	Participants with specific adverse events (description)	Participants with specific adverse events (N)	Participants with specific adverse events (%)
<b>Bolaman 2003</b>	I: oral vitamin B <sub>12</sub>	26 <sup>a</sup>	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	34 <sup>a</sup>	-	-	-
<b>Kuzminski 1998</b>	I: oral vitamin B <sub>12</sub>	18 <sup>b</sup>	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	15 <sup>b</sup>	-	-	-
<b>Saraswathy 2012</b>	I: oral vitamin B <sub>12</sub>	22 <sup>c</sup>	-	-	-
	C: intramuscular vitamin B <sub>12</sub>	27 <sup>d</sup>	-	-	-

- denotes not reported

C: comparator; I: intervention

<sup>a</sup>Ten participants in [Bolaman 2003](#) left the trial early, and the group assignment of the 10 participants was not reported

(Continued)

<sup>b</sup>Five participants in [Kuzminski 1998](#) were judged to have deficiency of primary folate rather than of cobalamin, therefore they were excluded from the data analysis

<sup>c</sup>Eight participants in this group left the trial early due to adverse events (n = 2), loss to follow-up (n = 4), and lack of subjective improvement (n = 2)

<sup>d</sup>Three participants in this group left the trial early due to expired (n = 1) and loss to follow-up (n = 2)

## Appendix 11. Survey of study investigators providing information on included trials

Trial ID	Date trial author contacted	Date trial author replied	Date trial author asked for additional information (short summary)	Date trial author provided data (short summary)
<b>Bolaman 2003</b>	18 March 2016	No reply	N/A	N/A
<b>Kuzminski 1998</b>	18 March 2016	No reply	N/A	N/A
<b>Saraswathy 2012</b>	23 December 2016	No reply	N/A	N/A

N/A: not applicable

## Appendix 12. Checklist to aid consistency and reproducibility of GRADE assessments

	Serum vitamin B <sub>12</sub> level	Clinical signs and symptoms of vitamin B <sub>12</sub> deficiency	Adverse events	Health-related quality of life	Acceptability	Socioeconomic effects
<b>Trial limitations (risk of bias)<sup>a</sup></b>	Was random sequence generation used (i.e. no potential for selection bias)?	Yes	N/R	Unclear	N/R	Unclear
	Was allocation concealment used (i.e. no potential for selection bias)?	Unclear		Unclear		Unclear

(Continued)

Was there blinding of participants and personnel (i.e. no potential for performance bias) or outcome not likely to be influenced by lack of blinding?	Yes		No (0)			Yes
Was there blinding of outcome assessment (i.e. no potential for detection bias) or was outcome measurement not likely to be influenced by lack of blinding?	Yes		No (0)			Yes
Was an objective outcome used?	Yes		No (0)			Yes
Were more than 80% of participants enrolled in trials included in the analysis (i.e. no potential reporting bias)? <sup>e</sup>	Yes		Yes			Yes
Were data reported consistently for the outcome of interest (i.e. no potential selective reporting)?	Yes		Unclear			Unclear

(Continued)

	No other biases reported (i.e. no potential for other bias)?	N/A		Yes			Yes
	Did the trials end as scheduled (i.e. not stopped early)?	Yes		Yes			Yes
<b>Inconsistency<sup>b</sup></b>	Point estimates did not vary widely?	N/A		N/A			N/A
	To what extent did confidence intervals overlap (substantial: all confidence intervals overlap at least one of the included studies point estimate; some: confidence intervals overlap but not all overlap at least one point estimate; no: at least one outlier: where the confidence intervals of some of the studies do not overlap with those of most included studies)?	N/A		N/A			N/A
	Was the direction of effect consistent?	N/A		N/A			N/A

(Continued)

	What was the magnitude of statistical heterogeneity (as measured by I <sup>2</sup> ): low (I <sup>2</sup> < 40%), moderate (I <sup>2</sup> 40% to 60%), high (I <sup>2</sup> > 60%)?	N/A		N/A		N/A
	Was the test for heterogeneity statistically significant (P < 0.1)?	N/A		N/A		N/A
<b>Indirectness<sup>a</sup></b>	Were the populations in the included studies applicable to the decision context?	Yes		Yes		Yes
	Were the interventions in the included studies applicable to the decision context?	Highly applicable		Highly applicable		Highly applicable
	Was the included outcome not a surrogate outcome?	Yes		Yes		Yes
	Was the outcome time frame sufficient?	Sufficient		Sufficient		Sufficient
	Were the conclusions based on direct comparisons?	Yes		Yes		Yes

(Continued)

<b>Imprecision<sup>c</sup></b>	Was the confidence interval for the pooled estimate not consistent with benefit and harm?	N/A		N/A		N/A
	What is the magnitude of the median sample size (high: 300 participants, intermediate: 100 to 300 participants, low: < 100 participants)? <sup>e</sup>	Low ()		Low ()		Low ()
	What was the magnitude of the number of included studies (large: > 10 studies, moderate: 5 to 10 studies, small: < 5 studies)? <sup>e</sup>	Small ()		Small ()		Small ()
	Was the outcome a common event (e.g. occurs more than 1/100)?	N/A		Yes		N/A
<b>Publication bias<sup>d</sup></b>	Was a comprehensive search conducted?	Yes		Yes		Yes
	Was grey literature searched?	Yes		Yes		Yes
	Were no restrictions applied to study selection	Yes		Yes		Yes

(Continued)

	on the basis of language?					
	There was no industry influence on studies included in the review?	Unclear		Unclear		Unclear
	There was no evidence of funnel plot asymmetry?	N/A		N/A		N/A
	There was no discrepancy in findings between published and unpublished trials?	N/A		N/A		N/A

( ): key item for possible downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of findings' table(s); N/A: not applicable; N/R: not reported

<sup>a</sup>Questions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials.

<sup>b</sup>Questions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on  $I^2$

<sup>c</sup>When judging the width of the confidence interval, it is recommended that a clinical decision threshold be used to assess whether the imprecision is clinically meaningful.

<sup>d</sup>Questions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry, and discrepancies between published and unpublished trials.

<sup>e</sup>Depends on the context of the systematic review area.

## WHAT'S NEW

Last assessed as up-to-date: 17 July 2017.

Date	Event	Description
26 October 2017	New search has been performed	In this update we included one additional trial.
26 October 2017	New citation required but conclusions have not changed	In this update we included a total of three trials.



## CONTRIBUTIONS OF AUTHORS

All review authors read and approved the final review draft.

Hai Yan Wang (HYW): trial selection, data analysis, data interpretation, quality of evidence assessment, and review writing.

Linyi Li (LYL): data extraction and 'Risk of bias' assessment.

Ling Ling Qin (LLQ): data extraction and 'Risk of bias' assessment.

Yanan Song (YNS): trial selection, 'Risk of bias' assessment, data analysis, data interpretation, and review update.

Josep Vidal-Alaball (JVA): protocol draft, search strategy development, acquiring trial reports, trial selection, data extraction, data analysis, data interpretation, review draft, and future review updates.

Tong Hua Liu (THL): trial selection, data analysis, quality of evidence assessment, and data interpretation.

## DECLARATIONS OF INTEREST

HYW: none known

LYL: none known.

LLQ: none known.

YNS: none known.

JVA: none known.

THL: none known.

## SOURCES OF SUPPORT

### Internal sources

- Department of General Practice, Wales College of Medicine, Cardiff University, UK.
- National Public Health Service for Wales, Wales, UK.
- Department of General Practice and Elderly Care Medicine, VU University Medical Center, Amsterdam, Netherlands.

### External sources

- No sources of support supplied

## DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The review authors' team changed for this update: Christopher C Butler, Rebecca Cannings-John, Andrew Goringe, Kerry Hood, Andrew McCaddon, Ian McDowell, Alexandra Papaioannou, Johannes C van der Wouden, and Rianne Langeveld are no longer review authors.

Since the last publication of this review (Issue 3, 2005), multiple changes such as new methods and other standards were introduced, leading to a complete renewal of this Cochrane Review. We have revised the search strategies for this review update. The following sections have also been changed.

- We used a cut-off point below 200 pg/mL (below 148 pmol/L) as a threshold serum level for vitamin B<sub>12</sub> deficiency to better differentiate vitamin B<sub>12</sub> deficiency from borderline deficiency.

- Types of outcomes: we added the section 'Method and timing of outcome measurement' to define each outcome and group the timing of outcome measurement.
- Types of outcomes: we added a 'Summary of findings' table.
- We updated the 'Assessment of risk of bias of included studies' section to provide further details about our judgements.
- We revised the 'Data extraction and management' section by specifying data items we planned to extract; adding two sections: 'Unit of analysis issues' and 'Dealing with missing data'; and other minor amendments.

## **NOTES**

We included a total of three trials in this update (one additional trial compared to the first published version in 2005).

## **INDEX TERMS**

### **Medical Subject Headings (MeSH)**

Administration, Oral; Injections, Intramuscular; Randomized Controlled Trials as Topic; Vitamin B 12 [\*administration & dosage]; Vitamin B 12 Deficiency [\*drug therapy]; Vitamin B Complex [\*administration & dosage]

### **MeSH check words**

Aged; Humans